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ABSTRACT
Mucosa-associated invariant T (MAIT) cells are innate-like T cells that are
activated by microbial vitamin B metabolites and/or cytokine stimulation to
produce pro-inflammatory cytokines and cytotoxic granules. Influenza A viruses
(IAVs) activate MAIT cells in a by-stander manner, and their abundance
negatively correlates with infection-induced morbidity and mortality. However,
how MAIT cells directly contribute to anti-viral immunity is ill-defined. I
hypothesized that MAIT cells’ presence in mice enhances antigen-specific CD8 +
T cell responses. I observed a trend that MAIT cell-deficient mice generally
developed smaller populations of antigen-specific CD8+ T cells following IAV
exposure than mice abundant in MAIT cells, with this difference being
pronounced amongst female mice. Co-administration of IAV and a potent MAIT
cell ligand did not influence the anti-IAV CD8+ T cell response, but induced rapid
MAIT cell accumulation in the peritoneal cavity. These results indicate that MAIT
cells are poised to influence anti-viral adaptive immune responses.
Keywords: mucosa-associated invariant T cell, 5-OP-RU, CD8+ T lymphocytes,
influenza A virus, peritoneal cavity, toll-like receptor
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SUMMARY FOR LAY AUDIENCE
Influenza A viruses are a major source of morbidity and mortality worldwide, with
annual infections keeping working people away from their jobs, sending others to
the hospital, and ultimately killing thousands. Influenza A viruses change very
quickly, which often allows them to be unaffected by anti-viral medications, and
also requires us to get new vaccines every year. Our ability to prevent and treat
influenza A viral infections is clearly poor and needs improvement. My research
evaluated how two different immune cells, CD8 + T cells and mucosa-associated
invariant T (MAIT) cells, work together to combat influenza A viruses. CD8 + T
cells are able to specifically detect and kill influenza-infected cells, and can be reactivated to fight future influenza infections. Influenza can activate MAIT cells to
release signals that have the potential to increase the virus-killing capacity of
CD8+ T cells. I found that mice that have many MAIT cells tended to have CD8 + T
cells with enhanced potential to kill influenza when compared to mice that lacked
MAIT cells. These findings indicate that targeting MAIT cells with anti-viral
medications and vaccines may promote the development of a killer CD8 + T cell
response that is capable of treating and preventing dangerous influenza A viral
infections.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW
1.1 INTRODUCTION
Mucosa-associated invariant T (MAIT) cells are innate-like T cells that express a
semi-invariant T cell receptor (TCR) and are abundant in human blood and
mucosae 1–3. Relatively little is known about this population of T cells, given that it
was shown for the first time only in 2012 that the MAIT cell TCR recognizes
microbial vitamin B metabolites presented by the MHC class I-related (MR1)
molecule 4. Due to their abundance in humans 1 and rapid reactivity to stimulation
5,

they have become a topic of intense investigation. Although originally labeled

as anti-microbial cells due to the bacterial and fungal origin of their activating
cognate ligand 4, a ground-breaking paper in 2016 showed that MAIT cells are
also activated by cytokines during viral infections and contribute to viral clearance
6.

Influenza A viruses (IAV) have been shown to cause MAIT cell activation,

which in turn appears to be protective against IAV-induced morbidity and
mortality 6–8. However, it remains unclear how MAIT cells benefit the anti-IAV
immune response, as they are unable to specifically detect and lyse IAV-infected
cells 6–8. My thesis project sought to determine whether MAIT cell presence
impacts antigen-specific cluster of differentiation 8 + (CD8+) T cells to influence the
anti-IAV immune response. Chapter 1 consists of a literature review that
summarizes the burden and dangers of IAV, as well as current limitations in how
it is clinically managed (section 1.2). The immune response as it relates to IAV is
then discussed, including how it could be further harnessed to improve protection
against the virus (section 1.3). MAIT cell biology is discussed due to the relative
novelty of this subset of T cells, and then recent data concerning their activity
during influenza A viral exposure is summarized (section 1.4). Finally, IAV, CD8 +
T cells and MAIT cells are linked together to provide the rationale for this project
(section 1.5).
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1.2 INFLUENZA A VIRUSES
1.2.1 Burden
Influenza A viruses circulate annually, infecting millions and killing hundreds of
thousands worldwide 9. Seasonal influenza infects people of all ages, but is more
likely to be associated with complications and death in high-risk patients, namely
children (6-23 months), pregnant women, the elderly (65+ years), and those with
pre-existing co-morbidities 10. In Canada, approximately 12,200 patients are
admitted to the hospital annually and an average of 3,500 lives are lost each year
due to the infection 11. Not only does influenza take a toll on the population, it is
also costly to the healthcare system and businesses. While estimates of costs
due to influenza vary, one review estimated that 19.8 billion United States dollars,
7.3 billion of which was attributable to work hours lost, was the cost incurred
during the 2010 influenza season in the United States 9. The influenza burden is
heavy and heavier still when pandemic IAV strains emerge, as was seen in 2009
when the “swine flu” circulated. During this year, emergency department visits
and the amount of time taken off work as a result of infection doubled in Canada
12,13.

Influenza A viral infections have proven themselves to be large health and

economic burdens that require better prevention and management.
1.2.2 Transmission, symptoms and pathophysiology
Influenza A viruses are transmitted among humans most commonly through
direct contact and droplets

14.

In Canada, influenza season tends to emerge in

the West and travels eastward as the year progresses

15.

Influenza transmission

thrives in low humidity and temperature, as well as in dense populations

15,16.

For

example, influenza is rapidly transmitted amongst children in schools, and there
is evidence that school closures effectively slow transmission of dangerous
pandemic IAV strains

16.

The IAV incubation period typically lasts about two days

before symptoms arise and viral shedding peaks

17.

Viral shedding persists for
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another four to five days and symptoms typically resolve during this time

17.

Although not everyone infected with IAV develops symptoms, many others will
experience upper (e.g. runny nose, sore throat, cough, sneezing) and lower (e.g.
cough, difficulty breathing) respiratory symptoms, as well as fever, myalgia, and
ear pressure abnormalities 17. The severity of these symptoms is expected to
vary based on viral pathogenicity, the size of the infectious dose, and pre-existing
health.
The cellular receptor necessary for IAV cell entry is abundant in the human
respiratory epithelium and the production of new viral progeny lyses respiratory
epithelial cells, causing influenza’s respiratory-associated symptoms

18.

Tracheobronchial inflammation and pulmonary function abnormalities ensue,
which can be especially dangerous in patients that already have weakened
cardiopulmonary function 18. Acute Respiratory Distress Syndrome can develop
in the case of severe bronchitis or viral pneumonia, which can lead to multi-organ
failure 18. Another common cause of IAV-associated death is secondary bacterial
pneumonia, which was common during the pandemic 1918 “Spanish flu”

19.

There is evidence of synergy between IAV and certain bacteria. Some bacteria
possess proteases that are able to enhance IAV infection by cleaving a viral
surface protein 20. In turn, IAV itself makes its host more susceptible to secondary
bacterial infection by exhausting the immune system and increasing lung damage
for improved bacterial adherence and invasion

21.

Viral infection is not the sole cause of symptoms and poor outcome in humans. In
many cases, especially in response to pandemic IAV strains, the human immune
system launches an inappropriately hyper-inflammatory response that
exacerbates the illness. In these cases, lung histopathology shows hoards of
inflammatory cells that leave no room for air

19.

These patients have high levels of

the serum chemoattractants monocyte chemoattractant protein 1 and interleukin8 (IL-8), which result in massive macrophage and neutrophil recruitment to the
lungs 22,23. Although the vast majority of patients maintain a localized IAV
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infection, a massive inflammatory response may overflow systemically.
Pharyngeal viral load in hospitalized patients with severe IAV infection correlates
with serum IL-10, IL-6 and interferon-γ (IFNγ) levels, suggesting that high viral
replication promotes hyper-cytokinemia 22. High levels of inflammatory cytokine
levels in patients infected with the 2009 pandemic influenza positively correlated
with poor prognosis and illness severity 23. There is evidence in humans and
mouse models that high levels of pro-inflammatory cytokines during IAV infection
increase ectopic trypsin levels and reduce vascular integrity, which both promote
edema and multi-organ failure

24.

It is true that the majority of IAV infections are

properly cleared in humans; however, especially virulent IAV strains can often
cause excessive damage and promote a deadly hyper-inflammatory immune
response.
1.2.3 IAV Virology
Influenza A viruses’ natural reservoir is in avian species; however over the years,
it has made multiple zoonotic leaps into the human population that have given
rise to both stable seasonal and dangerous pandemic IAV strains

18.

IAV is a

typically spherical, enveloped virus belonging to the Orthomyxoviridae family

18.

It

has a segmented, negative sense ribonucleic acid (RNA) genome that differs
from influenza B and C viruses in that it consists of a unique set of eight viral
RNAs (vRNAs) that code for 10 main proteins. The virus consists of three
components. The host-derived viral envelope contains the Neuraminidase (NA,10
subtypes) and Haemagglutinin (HA, 17 subtypes) proteins against which most of
the humoral immune response is directed, as well as the Matrix 2 (M2) protein

18.

IAV strains are named in part based on their HA and NA subtypes: type/(host if
non-human)/location where isolated/isolation number/year isolated/surface
antigen subtypes (e.g. A/Puerto Rico/8/1934/H1N1)

25.

Just beneath the viral

envelope and surrounding the nucleocapsids, the Matrix 1 (M1) protein forms the
matrix layer 18. The segmented genome is enclosed by the ribonucleoprotein
(RNP) core formed by Nucleoproteins (NP) and capped by the viral polymerase
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complex (Acidic Polymerase/PA, Basic Polymerase protein 1/PB1, and Basic
Polymerase protein 2/PB2) 18.
The PB1 gene has an additional open reading frame that leads to translation of
the PB1-frame 2 (PB1-F2) protein 26. PB1-F2 is incompletely understood, but
may increase host cell apoptosis, impact viral replication by interacting with other
polymerase proteins, and enhance the host pro-inflammatory response to
infection 18,26. Aside from the standard eight structural proteins and PB1-F2, Nonstructural protein 1 (NS1) works to prevent the host anti-viral interferon response
and regulates vRNA and protein synthesis

18,27.

Viruses lacking this important

protein are very attenuated 27. Finally, the Non-structural protein 2 (NS2) is a
nuclear export protein (NEP), responsible for removing vRNA from the nucleus
and delivering it to the cell membrane for progeny budding

18,28.

In humans, the IAV HA protein binds galactose α2,6-linked sialic acid receptors,
which are abundant in the respiratory tract, to trigger viral uptake by receptormediated endocytosis 18. HA then mediates viral fusion with the endosome, and
the M2 protein opens to acidify the virion interior, which releases RNPs into the
cytoplasm. The RNPs are transported into the nucleus via the nuclear pore
complex. Here, the RNA is transcribed into messenger RNA (mRNA) that is
transported out of the nucleus for viral protein translation. The RNA is also
transcribed into complementary RNA, which is then transcribed back into new
vRNA that gets packaged with newly translated RNP complex proteins. Finally,
vRNA-complexed RNPs are escorted out of the nucleus by NS2 to bud from lipid
raft-rich areas of the host cell membrane following cleavage by the NA protein.
IAV transcription is initiated on 7-methylguanosine caps stolen from host premRNAs by the viral PA

29,30.

The end of viral transcripts also possess a

polyadenylated tail created by the “stuttering” action of the viral polymerase,
which targets them for nuclear export

31,32.

It is also important to note that the

viral RNA polymerase is error-prone and frequently gives rise to mutation-ridden
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viral progeny, some of which are able to survive

33.

Due to this error-prone

polymerase and imposed selective pressure from the immune system, a new
assortment of slightly evolved IAVs circulates worldwide every year. This
constant viral evolution is referred to as “antigenic drift” and explains why
vaccines, which produce protective antibodies against the incessantly mutating
envelope proteins, require annual updates 18.
What is even more serious is when pandemic strains of IAV arise and infect the
human population. Since the beginning of the sixteenth century, more than a
dozen pandemic IAV strains have circulated in humans

18.

Most notable perhaps,

were the 1918 H1N1 “Spanish flu”, which is estimated to have killed more than 50
million people worldwide, and the more recent 2009 H1N1 “swine flu”, that killed
over 18,000 people 34,35. Pandemic IAV strains are so virulent because their
proteins are dissimilar to those previously seen by the human immune system

23.

In turn, the human body is unable to control the infection and in many cases,
develops a deadly hyper-inflammatory immune response

23.

Pandemic IAV is

suggested to arise due to an “antigenic shift” event, during which a cell that is
infected with multiple IAV strains gives rise to a new virion that contains gene
segments from each of the different IAVs

18.

Pig cells possess both galactose

α2,6 and α2,3-linked sialic acid receptors that allow for co-infection with human
and avian IAVs, respectively, thereby providing a “mixing vessel” to generate new
pandemic IAVs 36. These reassortment events produce dangerous IAVs that
contain foreign avian elements that wreak havoc in the human host. Both
seasonal and pandemic IAVs pose a serious threat to human health and have
thus made influenza prevention a large field of research.
1.2.4 Prevention
Livestock are the frequent source of pandemic IAV strains, making close
monitoring of swine and poultry a crucial step in preventing IAV transmission.
IAVs in these animals are regularly monitored for rapid genetic changes, genetic
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reassortment, and expression of HA proteins able to detect and enter human
cells in vitro 37. Mother pigs are vaccinated against IAV and subsequently pass
developed maternal antibodies onto their babies in an effort to reduce IAV burden
38.

IAV status is also very closely monitored at poultry farms and when highly

pathogenic avian influenzas are detected, entire flocks are immediately
euthanized 38. Aside from efforts to prevent IAV zoonosis, the best way to prevent
seasonal or pandemic influenza spread in humans is currently through
vaccination. The World Health Organization collects information concerning
emerging IAV strains and coordinates with other groups worldwide to develop
annual vaccines based on which IAV strains are predicted to circulate during the
upcoming year 18. The Canada Influenza Immunization guidelines for the 20182019 season recommend that everyone six months and older without
contraindications to the vaccine be immunized, with specific emphasis on highrisk populations and those capable of transmitting the virus to high-risk
populations 39.
Canadians are currently offered inactivated influenza vaccines (IIVs;
administered intramuscularly, with or without adjuvant) and live attenuated
influenza vaccines (LAIVs; administered intranasally) which are both designed to
develop antibody responses against the season’s prevalent influenza surface
proteins 39. The majority of IAVs used to develop these vaccines are grown in
embryonated hens’ eggs. IIVs contain split viruses (IAVs disrupted by detergents)
or subunit vaccines (purified HA and NA proteins). IIVs are available in both
trivalent and quadrivalent forms, each protecting against the predicted circulating
H3N2 and H1N1 IAV strains, as well as one or two influenza B virus strains.
These vaccines are very safe, with pain at the site of injection being the most
commonly reported side effect. The LAIV is a quadrivalent vaccine that contains
attenuated, cold-adapted viruses that are only able to replicate in the human
nasopharynx and not in the warmer environment of the respiratory tract

39.

These

viruses contain genes from an attenuated master donor virus and the two gene
segments coding for the seasonal HA and NA proteins

40.

This vaccine is thought
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to elicit a more natural anti-influenza immune response, as it more closely mimics
natural, mucosal infection. The vaccine is safe, with the most commonly reported
adverse events being runny nose and congestion

40.

Both IIVs and LAIVs are

effective at preventing influenza infection. Although offering more impressive
preventative power when a vaccine viral strain matches the infective strain,
seasonal vaccines are also moderately effective at preventing infection with
antigenically dissimilar IAVs

41.

While both vaccines are effective for all ages,

LAIV and IIV may be better suited for children and adults, respectively

41–46.

Vaccination is recommended for all people able to receive the immunization to
establish “herd immunity”, so that those unable to be vaccinated are protected
against infection by the collective immunity of the rest of the population

47.

The

United States proposes to annually vaccinate 80% of healthy individuals and 90%
of high-risk individuals, which should provide sufficient herd immunity

47.

However, current vaccination rates fall well below this mark, with as low as 10%
of healthy people and 39% of high-risk patients being vaccinated during a typical
influenza season 47. Barriers to vaccine uptake include the common recipient
beliefs that they will get the flu from the vaccine, that they feel healthy enough to
skip it, and that they may experience unwanted side effects after vaccination

48.

In addition, the Centers for Disease Control and Prevention carefully monitors
annual vaccine effectiveness based on the proportions of patients with reverse
transcription polymerase chain reaction (RT-PCR)-confirmed influenza infection
that either received or did not receive the influenza vaccine

49.

Their data,

commonly publicized by news outlets, indicate that vaccine effectiveness over the
last 15 years in the United States has ranged from only 10% to 60%, which can
certainly be disheartening for those deciding whether to get the seasonal
influenza vaccine. Although vaccination is currently the best way to prevent IAV
transmission, uptake must be improved and the search for a universal vaccine
needs to continue. After all, a novel, deadly pandemic IAV strain could arise at
any time, and vaccines would not be available to offer full protection to the
population until months after the first case is diagnosed, due to design and
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manufacturing delays 50. Vaccination is the best defense against IAV, especially
because current treatments for IAV infection are only moderately effective

51.

1.2.5 Detection and treatment
One of the first steps of clinical IAV management is diagnosis. IAV shares
symptoms with many other respiratory infections, so multiple methods of
diagnosis have been developed

52.

Tested specimens are collected by swabbing

or washing the nasopharynx to collect mucus. The specimen can then be plated
with influenza-susceptible cells, such as Madin Darby canine kidney (MDCK)
cells, to look for cytopathology in a viral culture system. However, this culture
system provides a diagnosis days after assay initiation and potentially past the
point of clinical utility. Rapid influenza detection tests are immunoassays that
detect IAV antigens in under 30 minutes. Although these tests are accessible,
inexpensive and easy to use, they lack high sensitivity and often require follow-up
to ensure correct diagnosis. More specific tests either stain nasopharyngeal
secretions with fluorescent antibodies specific for IAV antigens, or IAV RNA can
also be detected by RT-PCR. The latter two methods are sensitive, but lack the
speed of rapid influenza detection tests and require relatively expensive
laboratory equipment 52.
Generally, influenza symptoms may be partially relieved by non-steroidal antiinflammatory drugs and/or cough suppressants

18.

Corticosteroid treatment has

been suggested to suppress hyper-inflammation in critically ill patients in an effort
to prevent pneumonia or Acute Respiratory Distress Syndrome 53,54. However, this
would also prolong viral replication and there has been little evidence of its
efficacy to date 53,54. Specific anti-influenza medications, which limit viral
replication, are therefore the recommended treatment for hospitalized patients
who have a suspected/confirmed influenza infection or are in the high-risk
population 10. Two families of anti-IAV medications are currently available. The
adamantanes (Amantadine and Rimantadine) are M2 protein inhibitors that inhibit
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the virus from leaving the endosome after uptake

55.

Unfortunately, many

circulating H1N1 and H3N2 strains are resistant to adamantanes due to a
mutation in the viral M2 gene, which has limited the utility of these agents in the
clinic 56,57. Neuraminidase inhibitors (NAIs), such as inhaled Zanamivir and oral
Oseltamivir, interfere with the NA protein to inhibit viral progeny release from host
cells 58. Although there is some resistance to Oseltamivir 59, resistance to
Zanamivir is relatively low at this point in time 60.
While adamantanes are no longer recommended because of their high resistance
rates, NAIs are effective at reducing illness duration and severity of symptoms
with minimal side effects 61,62. They also have the potential to reduce IAVassociated complications, hospitalization in healthy and high-risk populations, as
well as mortality 63–65. However, their efficacy quickly diminishes after symptom
on-set 65. Given that viral load generally peaks 48 hours post-infection, patients
have a small timeframe to start anti-viral therapy to receive its benefits. Moreover,
many physicians do not prescribe NAIs because of their cost and/or because
they doubt their efficacy 66. Due to influenza’s rapid mutation rate, risk of drug
resistance, and lack of effective anti-viral medications when administration is
delayed, the need for improved anti-IAV therapies has become clear.
1.3 IMMUNE RESPONSES TO IAV
1.3.1 The innate immune response
Upon infection, IAV must penetrate the host respiratory tract’s mucosa and avoid
its anti-microbial peptides 18. If able to do so, IAV will infect the respiratory
epithelium, then replicate and give rise to progeny that will infect neighbouring
epithelial and receptive immune cells, including dendritic cells (DCs) and
macrophages 67. Through infection and phagocytosis of viral elements, the
epithelial and immune cell pattern recognition receptors (PRRs) detect IAV’s
pathogen-associated molecular patterns (PAMPs). IAV is recognized by multiple
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PRRs, including retinoic acid-inducible gene I (RIG-I), toll-like receptor 3 (TLR3),
TLR7 and the NACHT, LRR and PYD domains-containing protein 3 (NLRP3)
inflammasome.
RIG-I detects 5’-triphosphate single-stranded RNA in the cytosol of infected
epithelial cells, conventional DCs and alveolar macrophages to induce type I IFN
signaling and pro-inflammatory cytokine production

68,69.

TLR3 is expressed by

lung epithelial cells and DCs, and is stimulated by viral double-stranded RNA
detected during cellular infection and amongst phagocytosed apoptotic cell
remnants 70,71. TLR3 activation leads to the production of pro-inflammatory
cytokines and chemokines through NF-κB (nuclear factor kappa-light-chainenhancer of activated B cells) signalling 70. TLR7 is expressed primarily by
plasmacytoid DCs, that when stimulated by endosomal single-stranded RNA,
leads to the production of very large amounts of type I IFNs and pro-inflammatory
cytokines 72. Finally, the NLRP3 inflammasome is a protein complex that forms in
response to cell infection or stress to cleave pro-IL-18 and pro-IL-1β into their
mature forms for secretion. The NLRP3 inflammasome can be induced in myeloid
cells and human bronchial epithelial cells 73,74. Inflammasome activation is
important for promoting monocyte differentiation into DCs or macrophages, as
well as for neutrophil recruitment 75.
Together, the various PRRs stimulated by IAV cause type I IFN and cytokine
release. Type I IFNs promote an anti-viral state in neighbouring cells in an effort
to reduce further infection

76.

Type I IFNs initiate the translation of hundreds of

genes, called IFN-stimulated genes, including RNases and proteins that interfere
with viral attachment, transcription, budding and more

76.

Many cytokines and

chemokines are also released in response to IAV infection to recruit leukocytes to
the site of infection to aid viral clearance. Some important innate mediators
include IL-8 (that promotes neutrophil recruitment and phagocytosis), RANTES
(regulated upon activation, normal T cell expressed, and secreted; that recruits T
cells) and GM-CSF (granulocyte-macrophage colony-stimulating factor; that
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recruits granulocytes) 70,77. Phagocytic monocytes, macrophages and neutrophils
are among the first responders to quickly traffic to the lungs to clear virally-lysed
cells 78. Natural killer (NK) cells also quickly accumulate at the site of IAV
infection to destroy virally-infected cells

79.

The innate response to IAV infection is critical to viral clearance; however, its proinflammatory nature is also responsible for many influenza-associated symptoms.
For example, IL-6 and IFNα levels in patients’ nasal lavage fluid correlate with
temperature and symptom score 80. Inflammation is also a double-edged sword in
terms of survival. For example, TLR3 knock-out (KO) mice have reduced titers of
inflammatory cytokines and higher viral load, but also experience reduced
mortality rates compared with wildtype (WT) mice due to reduced inflammation

81.

Similarly, tumor necrosis factor (TNF) appears to promote neutrophil recruitment,
morbidity and tissue injury in mice, without any apparent benefit for viral
clearance or immunity 82. In severe cases, human infection with very virulent IAV
strains can lead to an inappropriate and detrimental “cytokine storm”, initiated by
macrophages that rapidly and aggressively respond to infection

83,84.

While the

innate arm of the immune response contributes both positively and negatively to
achieving good health following an IAV infection, adaptive immune cells are also
critical in striking the balance between hyper-inflammation and survival.
1.3.2 The adaptive immune response
Although slower to develop, adaptive immune cells offer antigen-specific effector
and memory capabilities that innate immune cells classically lack. In response to
PRR stimulation, DCs upregulate C-C chemokine receptor type 7 (CCR7)
expression to migrate to secondary lymphoid tissues to activate antigen-naïve B
cells, CD4+ T cells, and CD8+ T cells 18,85. DCs upregulate antigen presenting
molecules to express IAV-derived peptides, as well as co-stimulatory molecules,
to activate antigen-specific adaptive immune cells to differentiate into effector
cells 86.
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Naïve CD4+ T cells are activated by and proliferate in response to viral antigen
recognition in the context of major histocompatibility complex (MHC) class II
molecules when additional co-stimulatory molecules and cytokines are also
present 87. CD4+ T cells can be cytolytic and produce large amounts of IFNγ to
contribute directly to viral clearance 88–90. They give rise to memory populations
capable of rapidly recognizing and clearing IAV to reduce the viral burden in mice
and humans 90,91. CD4+ T cells also have a significant role in promoting the
activation of B cells and CD8+ T cells. CD4+ T cell TCRs bind peptide-MHC class
II complexes on B cells to provide B cells with cytokine and co-stimulatory signals
92.

They promote B cells to undergo somatic hypermutation, to enhance their

antigen affinity, and antibody class switching, to promote the production of highaffinity antibodies with various effector functions

92.

CD4+ T cells also provide

help to CD8+ T cells that encourages more effective acute and memory
responses 18.
B cells are activated in the secondary lymphoid tissues with the help of CD4 + T
cells and antigen presentation by follicular DCs

93.

B cells that recognize their

specific peptide antigen undergo proliferation and somatic hypermutation, either
becoming memory B cells or plasma cells 94,95. Plasma cells produce large
amounts of antibodies that contribute to primary infection viral clearance

93.

Some

plasma cells persist in the bone marrow following infection clearance and
continuously secrete antibodies that can quickly neutralize subsequent infectious
IAVs that express similar envelope proteins to those of the initial infectious virus
93,96.

The long-lived memory B cell response is continuously attuned with

repeated influenza exposures and capable of giving rise to plasma cells that
produce very high affinity anti-IAV antibodies

93,97–99.

The majority of antibodies

produced by plasma cells during IAV infection are Immunoglobulin M (IgM), IgA
or IgG 100. Antibodies bind to their specific viral antigens to neutralize the virus,
label target cells for NK cell-mediated killing (antibody-dependent cellular
cytotoxicity), opsonize targets for phagocytosis, or trigger complement activation
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18.

In addition, B cells release cytokines and act as antigen presenting cells

(APCs) to promote effective CD4+ and CD8+ T cell responses 93,101.
Today’s influenza vaccinations elicit memory B cell responses against the viral
envelope proteins 39. Due to antigenic drift, the influenza vaccine requires
updates every year to account for changes in the HA and NA protein structures.
Although offering some protection against “mis-matched” IAV strains, these
envelope-directed responses are most effective at preventing IAV infection when
the infectious viral envelope proteins match those of the vaccine

102.

The antibody

responses appear to be long-lived as well. During the 2009 IAV pandemic, many
people born before 1950 had already developed antibodies that were crossreactive with the 2009 H1N1 IAV, which led to less morbidity and mortality in this
cohort than would have normally been expected

103.

The most protective

antibodies are directed against conserved portions of the HA protein and are
therefore effective against annual drift variants

104.

However, annual vaccines fail

to reliably develop these antibodies, which instead appear to be derived in small
numbers from long-lived memory B cells that have undergone extensive somatic
hypermutation through years of IAV exposure 103,104. So, although vaccine-elicited
antibody responses can be effective at preventing IAV infection, they often prove
ineffective against drift variants, which is problematic when considering the
incredible speed at which IAV evolves. The antibody response also takes a long
time to develop and lags behind the antigen-specific CD8 + T cell response
93,105,106.

1.3.3 Spotlight: The CD8+ T cell response
The CD8+ T cell response is a critical component of the adaptive immune
response to IAV infection. The CD8+ T cell response is initiated in secondary
lymphoid tissues, just as with CD4+ T cells and B cells. DCs are infected with or
pick up IAV antigens in the respiratory tract and migrate to the secondary
lymphoid tissues where they upregulate the expression of CD40, CD80 and
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CD86, which are markers of maturation and co-stimulation

107.

Proteasomes in

each DC degrade viral antigens into short peptides 7-11 amino acids in length,
which the Transporter Associated with Antigen Processing (TAP) protein then
grabs and shuttles from the cytosol into the endoplasmic reticulum for loading
onto MHC class I molecules 18. Naïve CD8+ T cells that express a TCR capable
of detecting a cognate MHC class I-peptide complex presented on the membrane
of DCs will engage with the APC and receive co-stimulatory signals

108.

CD8+ T

cells that optimally detect their activating viral peptide in the context of MHC class
I proliferate and egress from the secondary lymphoid tissues

109.

They upregulate

CCR5 to be recruited to the lungs by C-C chemokine ligand type 5 (CCL5), where
they continue to proliferate and fight IAV, peaking in the lungs of mice 9-11 days
post-infection 109,110.
One interesting aspect of the anti-IAV CD8+ T cell response is its
“immunodominance” governance. It may be expected that given all the potential
viral peptides that could be presented to CD8+ T cells, there are thousands of
effector CD8+ T cell clones capable of detecting each single IAV peptide.
However in reality, the entire anti-IAV CD8+ T cell response is directed against
only a handful of viral epitopes 111. Peptides may be dominant, co-dominant, or
sub-dominant, and the type of infection influences the dominance hierarchy

112.

There are multiple factors influencing which peptides cause clonal CD8 + T cell
proliferation and the shape of the immunodominance hierarchy, including a
peptide’s ability to be processed by APCs and loaded onto MHC class I
molecules with sufficient affinity 111,113, and the relative abundance of viral
epitopes and CD8+ T cells capable of recognizing them

114,

among many more.

Immunodominance must be considered when designing CD8+ T cell-mediated
anti-viral medications and vaccinations, to ensure that (1) target viral proteins are
capable of eliciting strong/dominant CD8+ T cell responses and (2) that the
response is generated against multiple immunogenic peptides or a conserved
peptide to avoid directing the entire CD8+ T cell response against a single peptide
that may be lost through viral evolution. In addition, immunodominance
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hierarchies vary within the human population due to polymorphisms in MHC class
I molecules, making the challenge of creating broadly-applicable anti-viral
therapies even more problematic 115. Despite the constraints of
immunodominance, the efficacy of the anti-IAV CD8+ T cell response is still
evident.
Although naïve CD8+ T cells require prolonged antigen exposure to be activated
for the first time, once differentiated into effector CD8 + T cells, they require much
less antigen stimulation before becoming activated

108.

In response to cognate

antigen recognition, effector CD8+ T cells produce inflammatory anti-viral
cytokines. The majority of these T cells will produce IFNγ, a smaller subset of
those will additionally produce TNFα, and a smaller subset of that population will
also produce IL-2, with the most polyfunctional T cells providing the most
effective protection against IAV

116,117.

These cytokines play many different roles

to ultimately promote infected cell death, recruit and activate other immune cells
and induce proliferation of cytotoxic immune cells

118.

CD8+ T cells also directly

engage with virally-infected cells to mediate target cell apoptosis through the
immune synapse. CD8+ T cells release perforin to allow secreted granzymes to
enter target cells and initiate apoptotic death 119. They also upregulate FasL (first
apoptosis signal ligand) and TRAIL (TNF-related apoptosis-inducing ligand)
expression to ligate target cell death receptors Fas and death receptor 5,
respectively, to also induce apoptosis in infected cells

119,120.

The importance of CD8+ T cell-mediated immunity can be derived from studies in
β2-microglobulin KO mice, which have defective MHC class I presentation and
thus give rise to poor CD8+ T cell responses. Although CD8+ T cells do not
appear to be essential to fighting IAV, as β2-microglobulin KO mice are able to
survive some IAV infections

121,

CD8+ T cells are important in viral clearance and

reducing mortality during lethal IAV challenges

122.

Additionally, adoptively

transferring effector and memory antigen-specific CD8 + T cells into naïve mice
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subsequently challenged with lethal homologous IAV increases their survival and
reduces their viral load 123.
Despite the obvious benefits of a strong anti-influenza CD8+ T cell response, a
hyper-active response can lead to immunopathology, as with the innate immune
response. When able to control IAV replication in a timely manner, CD8 + T cells
are protective in mice 124. However, if they fail to control viral infection (e.g. high
inoculation dose), they increase pathology by rapidly increasing inflammation,
lung leukocyte infiltration, and ultimately, mortality in mice

124.

Their prolonged

activation and cytokine production (e.g. IFNγ and TNFα) increases lung epithelial
damage and promotes dangerous levels of leukocyte infiltration

84,124,125.

The

ability to suppress hyper-activated CD8+ T cell responses during acute IAV
infection could be an effective way to treat patients that are critically ill with IAV.
However, even more effective, would be designing a vaccine that promotes the
development of a strong memory CD8+ T cell response that could prevent IAV
infections altogether.
Following an acute IAV infection, memory CD8+ T cells will persist to prevent reinfection. After viral clearance, most effectors die by apoptosis and a subset of
antigen-specific CD8+ T cells acquire a memory phenotype in the weeks following
viral clearance 18,126. Some antigen-specific memory CD8+ T cells persist in the
lungs with the ability to proliferate, secrete cytokines and become cytolytic upon
target recognition

127.

Memory CD8+ T cells are also recruited to the lungs during

secondary infection and can in fact be activated by innate signalling from IFNs to
enhance their cytolytic ability 128. The larger this memory CD8+ T cell pool, the
greater protection through rapid viral clearance

129.

Many memory CD8+ T cells

also appear to be generated against conserved internal proteins shared by
multiple IAVs in humans, making the memory CD8 + T cell pool a very attractive
vaccine target 130. Interestingly, primary lung infection is not necessary to
establish memory CD8+ T cell populations in the lungs, suggesting that vaccines
can elicit protective memory populations 127. During the 2009 H1N1 pandemic,
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amongst patients that lacked protective antibodies, the amount of pre-existing
CD8+ T cells that detected conserved influenza epitopes correlated negatively
with illness severity, implicating the importance of CD8+ T cells in heterosubtypic
immunity 131. However, current vaccinations are unable to elicit strong memory
CD8+ T cell responses 44,132. Memory CD8+ T cells hold a lot of potential in that
they can rapidly detect and clear IAV through recognition of conserved viral
epitopes, such as portions of the M2 and HA proteins

133.

CD8+ T cells have the

potential to develop into very effective memory cells able to detect a plethora of
IAVs, making the hunt for a vaccine that produces strong memory anti-IAV CD8 +
T cell responses a very attractive pursuit

132.

1.4 MAIT CELLS
1.4.1 Introduction and historical perspective
Mucosa-associated invariant T (MAIT) cells are a highly conserved subset of T
cells in mammals that express a semi-invariant TCR and share many similarities
with invariant Natural Killer T (iNKT) cells 134. In humans, the MAIT cell TCR most
often has a Vα7.2-Jα33 linkage, but occasionally possess a Vα7.2-Jα12 or -Jα20
linkage 2,3. The mouse MAIT cell TCR α chain has a Vα19-Jα33 linkage

135.

The

TCR α chains preferentially associate with a couple of Vβ regions, including Vβ2
and Vβ13 in humans, and Vβ6 and Vβ8 in mice

136.

The human invariant Vα7.2-

Jα33 TCR was first shown to be enriched within the double negative (CD4 -CD8-)
α/β T cell population in multiple donors in 1993 2. Ten years later, these cells
were termed “mucosa-associated invariant T cells”, due to their high abundance
in the mucosal tissues of the gut

137.

At this time, it was also shown that selection

and expansion of MAIT cells were dependent on the non-classical MHC class Irelated molecule (MR1) 137. In 2012, it was finally shown that MR1 presents
vitamin B biosynthesis metabolites produced by many bacteria and some fungi to
MAIT cells, which accordingly respond by secreting TNFα and IFNγ in a TCRdependent manner 4. Therefore, MAIT cells were initially touted as anti-microbial
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cells abundant in mucosal tissues. However in 2014, it was shown that MAIT
cells could be activated independent of any TCR stimulation

138,

and just two

years later, MAIT cells were shown to be activated in a TCR-independent manner
during viral infections 6,7.
1.4.2 The MHC class I-related molecule
MR1 is an evolutionarily conserved antigen presentation molecule that presents
vitamin B metabolites to MAIT cells 4,139. The MR1 gene is located on
chromosome 1 in both mice and humans, and its ligand binding domain shares
90% sequence identity between the two species

139.

Despite being ubiquitously

expressed 139, MR1 must be stably folded in the presence of one of its ligands to
reach the cell membrane 137,140. Similar to MHC class I molecules, MR1
associates with β2-microglobulin 137. However, MR1 surface expression is not at
all dependent on the proteasome or TAP complexes, which corroborates the nonpeptide origin of MR1 ligands 141. Although not necessary, it has been shown in
vitro that Invariant chain and Human Leukocyte Antigen DM overexpression
enhance MR1 surface expression and MAIT cell activation

141.

These two

molecules are involved in MHC class II molecule loading; the Invariant chain
blocks antigen loading onto MHC class II molecules in the endoplasmic reticulum
until they reach the late endosomal compartment, when Human Leukocyte
Antigen DM unblocks the antigen-binding pocket to allow peptide loading. Also
similar to MHC class II presentation, MR1 surface expression is reduced by
blocking endosomal acidification

141.

Although MR1 antigen loading and

trafficking is currently poorly understood, it would appear the processes share
similarities with both MHC class I and II processing.
The MAIT cell TCR docks centrally and orthogonally to MR1, similarly to
conventional TCR and MHC docking

142.

When presenting a stimulatory MAIT cell

ligand, the MAIT cell TCR makes direct contact with the antigen and binds to
MR1 with similar affinity as is seen with conventional MHC and TCR interactions
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142.

Interestingly, MR1 is stably expressed at the cell membrane even when

bound with non-stimulatory ligands 4,142. However, these ligands do not make
contact with the MAIT cell TCR and the MR1-antigen complex binds accordingly
with poor affinity to the MAIT cell TCR 142. The currently known stimulatory MAIT
cell ligand occupies only one of two pockets in the MR1 antigen-binding groove
143.

This may indicate that there are other meaningful MAIT cell ligands yet to be

discovered.
1.4.3 Development and regulation
MAIT cells develop in the thymus where they undergo positive selection on
double positive (CD4+CD8+) thymocytes that express high levels of MR1

144.

MAIT cells egress from the human thymus with a naïve phenotype (CD45RO lo,
CD45RA+, CD27+), expand in the periphery during the first few years of life, and
adapt a mature effector memory phenotype (CD45RA-, CD45RO+, CD95hi,
CD62Llo) 145–147. In mice, MAIT cells leave the thymus as already mature cells
and do not expand in the periphery to the same extent as is seen in humans
135,148,149.

Aside from the necessity of MR1, MAIT cells also require a microbiome

presence to expand, as germ-free mice lack MAIT cells

137,150.

However,

inoculating them with only one bacterial strain that is capable of generating
vitamin B metabolites for presentation by MR1 restores MAIT cell levels in mice
137,150.

MAIT cells are typically either CD8+ or double negative (CD4-CD8-), and express
multiple master transcription factors, including promyelocytic leukemia zinc finger
(PLZF), RAR-related orphan receptor γ (RORγt), and T-box transcription factor
(T-bet) 3,151. PLZF regulates innate-like T cells, and is also expressed by iNKT
cells 152. PLZF is required for functional MAIT cell maturation in mice

149.

RORγt

is associated with the Type 17 phenotype (mucosal and anti-bacterial immunity)
145,149,153.

In contrast, T-bet is associated with the inflammatory Type 1
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phenotype, and although human MAIT cells may express both T-bet and RORγt,
mouse MAIT cells tend to only express one or the other

151.

1.4.4 Identification and abundance
Originally, PCR was used to amplify the MAIT cell TCR sequence to assess
MAIT cell abundance 2. Eventually, MAIT cells were recognized to express high
levels of CD161 in humans and have subsequently been quite accurately
identified as CD161hiVα7.2+ cells, easily identified by flow cytometry

147.

However,

the preferred method to detect MAIT cells is now with MR1 tetramers 3. Prior to
the advent of MR1 tetramer reagents, accurate identification of mouse MAIT cells
was hindered by the lack of a CD161 analog 148. In addition, not all Vα7.2+ cells
are MAIT cells, because some conventional human T cells possess Vα7.2. MAIT
cells are therefore truly defined by their ability to recognize antigens presented by
MR1. To date, the most potent known MAIT cell TCR agonist presented by MR1
is 5-OP-RU. 5-OP-RU is a pyrimidine adduct produced by the non-enzymatic
reaction between methylglyoxal, produced by multiple metabolic pathways, and
5-A-RU, a product of the riboflavin biosynthesis pathway present in many
bacteria and fungi 4. MR1 tetramers presenting 5-OP-RU have been developed
for both mice and humans to specifically detect MAIT cells 3. MR1 tetramers are
considered the gold standard for MAIT cell identification (Figure 1).
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Figure 1: Mouse MAIT cells are identified by MR1 tetramers presenting 5OP-RU. MAIT cells are innate-like T cells with an effector-memory phenotype,
characterized by their expression of CD45RO+, CD95HI and CD62LLO 145–147.
MAIT cells are regulated by the PLZF, RORγt and T-bet transcription factors
3,151. Mouse MAIT cells express an invariant TCR with a Vα19-Jα33 linkage
135. Fluorochrome-conjugated MR1 tetramers presenting 5-OP-RU are
recognized and bound by the MAIT cell semi-invariant TCR to identify MAIT cells
3.
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Although MAIT cell frequencies certainly vary within the human population, they
can represent 1-10% of T cells in the peripheral blood, up to 10% in the gut, 2050% in the liver, and 2-4% of T cells in the lungs of humans 1. In contrast, they
are very infrequent in conventional laboratory mouse strains, making up less than
1% of T cells in the spleen, liver and gut, with a maximum of 3.3% of T cells in
the C57BL/6 mouse lungs 1. The reason for their relative scarcity in mice is not
due to different microbiome components or abundance of MAIT cell antigens as
was previously hypothesized, but may rather be due to a genetic bottleneck in
these species that reduced the amount of MAIT cell TCR rearrangements

148.

Due to the poor detectability of MAIT cells in mice, multiple approaches have
been taken to generate mouse models that better mimic the MAIT cell
frequencies that are seen in humans.
Originally, Vα19 and/or Vβ6 transgenic mice were generated, in which the only
expressed TCRα chain was Vα19. However, MAIT cells in these animals were
forced through an unnatural ontogeny, which called their relevance into question
147,154.

As well, these mice only possessed T cells expressing the MAIT cell

invariant TCR, which precluded study of MAIT cell interactions with other T cells
147,154.

More recently, some researchers have begun infecting WT C57BL/6 mice

intranasally with Salmonella typhimurium, which results in MAIT cell accumulation
in the lungs 155. They then harvest these MAIT cells and adoptively transfer them
into naïve mice, on which they perform experiments 8. The caveats of this model
are that MAIT cell responses are now being evaluated after prior antigen
exposure and that adoptive transfer may not be populating tissues with MAIT
cells in a way that would be found naturally. Finally, in 2015, a group in France
found that Mus musculus castaneus (CAST/EiJ) mice have 20 times more MAIT
cells than C57BL/6 mice

148.

This trait was chromosome-intrinsic and

subsequently backcrossed onto a C57BL/6 background. The MAIT hi trait was
traced to a locus on chromosome 14 that appeared to result in increased usage
of the distal Vα segment. Because Vα segments rearrange sequentially with Jα
segments, and Vα19 is the most distal segment, these mice just appeared to
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produce more of the MAIT cell TCR. This phenomenon is incompletely
understood but has led to the production of a mouse model that has detectable
levels of MAIT cells that undergo natural ontogeny. These mice harbour
quintessential MAIT cells that express the key transcription factors PLZF, RORγt,
and/or T-bet, and their MAIT cells are easily identified with MR1 tetramers

151.

On

this B6-CAST background, MR1 KO mice were also generated. MR1 is required
for positive selection of MAIT cells during development and when it is absent,
MAIT cells die by neglect in the thymus, resulting in mice that are devoid of MAIT
cells 148.
1.4.5 TCR-dependent stimulation
Unlike conventional MHC molecules that present protein antigens and CD1
molecules that present lipid-based antigens, MR1 binds and presents vitamin B
metabolites 4. The most potent MAIT cell ligand, 5-OP-RU, is derived from the
bacterial riboflavin (vitamin B2) biosynthetic pathway that is present in many
bacteria and fungi, but not in human cells 4. Interestingly, MAIT cells may also be
activated by non-vitamin B metabolites, as metabolites of the drug Diclofenac and
other small molecules have been shown to bind MR1 and activate MAIT cells

156.

Impacts of this drug and any other molecules that may stimulate MAIT cells will
need to be a focus of investigation as more is uncovered about MAIT cells.
Human MAIT cell TCR artificial stimulation (with CD3 and CD28) leads to the
production of cytotoxic granules and both Type 1 and 17 cytokines, including
granzyme B (GzmB), perforin, IFNγ, TNFα, IL-2, and IL-17

145,157.

MAIT cells are

also potently activated when co-cultured with human cells exposed to bacteria
that can produce 5-OP-RU. MAIT cells degranulate to kill Henrietta Lacks cells
co-cultured with Escherichia coli (non-invasive bacteria) or Shigella flexneri
(invasive bacteria) 157. MAIT cells also proliferate, as indicated by the
upregulation of the proliferation marker, Ki-67 +, in a dose-dependent, TCRdependent manner following exposure to Escherichia coli co-cultured monocytes
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5.

Although readily activated through TCR stimulation, MAIT cells can also be

activated in a TCR-independent manner.
1.4.6 TCR-independent stimulation
MAIT cells are potently activated by various innate cytokines, with the most
notable/potent ones being IL-12 and IL-18

138.

MAIT cells express high levels of

IL-12 and IL-18 receptors and produce large amounts of IFNγ and GzmB when
bound by cytokine in a completely MR1-independent manner

138,158.

TLR

stimulation appears upstream of cytokine-dependent MAIT cell activation. MAIT
cells from human peripheral blood mononuclear cells (PBMCs) produce IFNγ in
response to TLR8 stimulation with single stranded RNA; however, this activation
is inhibited by IL-12 or IL-18 neutralization

138.

Blocking endosomal acidification

or preventing inflammasome-mediated release of IL-18 also blocks MAIT cell
activation. In the same set of experiments, TLR2, 3, 4 and 5 agonists could also
stimulate MAIT cell IFNγ production, although minimally 138. Many viruses
commonly stimulate TLRs, causing the release of cytokines that have been
observed to activate MAIT cells. So, these initial studies provided the first
evidence that MAIT cells could potentially play a role in the immune response to
non-microbial infections.
MAIT cells cannot respond to viruses in a TCR-dependent manner, because MR1
does not present viral antigens

4,145,159.

However, following the discovery that

MAIT cells can be activated in a TCR-independent manner, it was shown for the
first time in 2016 that human MAIT cells can in fact be activated in a by-stander
fashion by viruses, including Hepatitis C, Dengue and influenza A viruses 6.
During human viral infections, peripheral blood MAIT cell frequencies tend to be
decreased relative to healthy controls; however, the MAIT cells that are present
appear to be activated 6,160. Furthermore, PBMCs isolated from healthy donors
and co-cultured with any of the three viruses tested led to MAIT cell activation as
judged by the production of GzmB, IFNγ and TNFα, an effect that could not be
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ablated by blocking MR1 6. Only blockade of IL-18 alone, or in conjunction with
IL-12 or IL-15, reduced the frequency of MAIT cells producing IFNγ by 40-100%
for each virus. Considering the importance of the anti-viral IFN response, it was
also shown that in combination with IL-12 or IL-18, IFNα or IFNβ could enhance
MAIT cell activation. Importantly, when sorted MAIT cells were stimulated with IL12 and IL-18, the transfer of their supernatant to hepatocytes infected with
Hepatitis C virus suppressed viral replication 6. This ground-breaking paper was
the first to show that not only are MAIT cells activated by viral infection, they also
directly contribute to anti-viral immunity.
1.4.7 MAIT cells and influenza A viruses
To date, two groups have evaluated the role of MAIT cells in anti-IAV immunity
8.

6–

The first studies investigated severe human IAV infection. Hospitalized patients

with severe IAV infections all appeared to have lower levels of peripheral blood
MAIT cells that healthy control donors

6,7.

Amongst infected patients, those with

the lowest levels of MAIT cells were at a higher risk of succumbing to their illness,
while patients with higher levels of MAIT cells were more likely to recover quickly
and survive their infections 6,7. In vitro, MAIT cells co-cultured with IAV-exposed
PBMCs or macrophages showed signs of activation, namely CD69, IFNγ, TNFα
and GzmB upregulation, although no significant upregulation of the degranulation
marker CD107a was detected

6,7.

MAIT cell IFNγ production could be

incompletely reduced by blocking IL-18, which was mainly produced by CD14 +
monocytes in culture 7. Again, MAIT cell activation was unaffected by blocking
MR1 6,7.
A recent study investigated the role of MAIT cells during IAV infection in vivo, and
was actually the first study to evaluate the role of MAIT cells in a mouse model of
viral infection 8. Mice were intranasally infected with IAV and MAIT cells were
shown to accumulate in the lungs, peaking on day five post-inoculation. These
cells were active, as indicated by their expression of CD25 and CD69. MAIT cell
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accumulation was absent in IL-18 KO mice. Interestingly, MR1 KO mice had
increased mortality relative to WT mice; however, MAIT cell adoptive transfer into
MR1 KO mice was partially protective. MAIT cell presence did not influence lung
viral titer but did seem to reduce lung damage. The authors suggested that the
apparent benefit of MAIT cells on anti-IAV immunity was attributable to MAIT cell
IFNγ production, as adoptive transfer of IFNγ KO MAIT cells into T cell-deficient
mice was not as protective against IAV challenge as was transfer of WT MAIT
cells 8. Taken together, these studies suggest that MAIT cells are beneficial to the
anti-IAV immune response. However, it remains unknown exactly how MAIT cells
are exerting their positive influence.
1.5. PROJECT RATIONALE
1.5.1 Evidence to support the IAV-CD8-MAIT interaction
MAIT cell abundance in the peripheral blood appears to positively correlate with
human IAV prognosis and lack of MAIT cells increases mortality in mice,
suggesting that MAIT cells play a protective role during influenza A viral infection
6–8.

However, MAIT cells are unable to recognize specific viral antigens and

therefore cannot direct a cytolytic response against virally-infected cells. How
MAIT cells specifically enhance the anti-IAV immune response remains unknown.
We suggest that MAIT cells may be enhancing the activity of another subset of
immune cells, namely CD8+ T cells, which can exert a direct anti-viral response.
To date, nobody has investigated the exact relationship between MAIT cells and
CD8+ T cells, especially in the context of viral infection. It was shown that MR1
KO mice infected with Francisella tularensis, which produces a lung infection and
can activate MAIT cells in a TCR-dependent manner, experience delayed CD8 + T
cell recruitment to the lungs and IFNγ production when compared to WT mice
Intriguingly, Wilgenburg et al. suggested that MAIT cell-derived IFNγ confers a
survival advantage to mice during IAV infection 8. IFNγ plays an important and

161.
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complex role in fighting IAV; however, it has been shown that IFNγ KO mice
infected intranasally with IAV accumulate less epitope-specific CD8 + T cells in the
bronchoalveolar lavage relative to WT mice, perhaps due to reduced trafficking
from secondary lymphoid tissues

162.

In addition, iNKT cells, which share many

phenotypic similarities with MAIT cells, appear to improve anti-IAV CD8 + T cell
responses 163. Mice lacking iNKT cells develop similarly sized CD8+ T cell
responses when challenged with IAV; however, their cytolytic ability is reduced
relative to WT mice 163. Ishikawa et al. also attributed this positive effect of iNKT
cells to their production of IFNγ. Taken together, there is preliminary evidence to
suggest that MAIT cell activation during IAV infection may enhance the specific
anti-IAV CD8+ T cell response (Figure 2).
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Figure 2: MAIT cells have the potential to modulate anti-IAV CD8+ T cell
responses. MAIT cells are known to be activated by IL-18 released during IAV
infection 6–8. In response, MAIT cells may produce IFNγ 6–8,138 which could
enhance targeted CD8+ T cell responses. In addition, concurrent 5-OP-RU and
IAV administration may optimally activate MAIT cells 158 to produce larger
amounts of IFNγ that subsequently enhance anti-IAV CD8+ T cell activity.
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1.5.2 Importance of studying MAIT cells in the context of IAV infection
MAIT cells are present in the mucosa of the lungs and possess the ability to
rapidly respond to natural IAV infection in a way that has the potential to shape
the resulting anti-IAV adaptive immune response 8. I investigated the potential
relationship between MAIT cells and CD8+ T cells in the context of IAV exposure
for two main reasons. First, since the human MAIT cell population is relatively
homogenous in that every person’s MAIT cells can be activated by the same
stimuli (e.g. 5-OP-RU, cytokine stimulation), this subset of T cells could be a
great clinical target. This is in stark contrast to the very heterogenous
conventional B cell, CD4+ and CD8+ T cell populations. If MAIT cell activation or
inhibition impacts the anti-IAV CD8+ T cell response, MAIT cell modulation with
vaccine adjuvants or in patients with severe IAV infections could offer a way to
universally control IAV infection. The second reason why this project is attractive
is because it will contribute to the expanding knowledge of MAIT cell biology.
MAIT cells are abundant in the human body, and the roles that they play in the
immune response to bacterial and especially viral infections are just starting to
emerge. MAIT cells are a poorly understood subset of T cells; however, this
project will contribute to the understanding of their basic function.
1.5.3 Hypothesis and objectives
I hypothesized that MAIT cells enhance specific CD8+ T cell responses to IAV.
I had three objectives:
1. To investigate the impact of MAIT cell presence and absence on the
magnitude, breadth and efficacy of CD8+ T cell responses to IAV in mice.
2. To determine whether anti-IAV CD8+ T cell responses can be manipulated
by concurrent TCR-dependent and -independent MAIT cell activation.
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3. To investigate the properties of a newly discovered population of MAIT
cells shown to accumulate in the peritoneal cavity in response to IAV and
TCR-dependent stimulation.
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CHAPTER 2: METHODS
2.1 ANIMAL EXPERIMENTS
Rorγt-GFPTG/B6-MAITCAST/MR1+ or MR1- mice (referred to throughout this thesis
as B6-CAST and MR1 KO mice, respectively) were kindly provided by Dr. Olivier
Lantz (Curie Institute, France) and bred in a specific pathogen-free barrier facility
in-house (see section 1.4.4 for phenotype information)

148.

When required,

C57BL/6 mice (referred to throughout this thesis as WT B6 mice) were ordered
from Charles River Laboratories and housed in the same facility. Sexuallymatured sex- and age-matched (6-14 weeks) mice were used in all experiments.
Mice were euthanized by cervical dislocation at their humane or experimental
endpoints. Experimental procedures were approved by the Animal Care
Committee at Western University (protocol numbers 2010-241 and 2018-093;
Appendices 1 and 2).
2.2 MEDIA, CELL LINES AND REAGENTS
2.2.1 Standard equipment and procedures
Unless otherwise stated, the following equipment and protocols were used to
process all cells where applicable. Cells were incubated in a HERACELL 150
incubator (Thermo) set at 37° C with 6% CO2. Cells were re-suspended in
Dulbecco’s phosphate-buffered saline (PBS; Sigma). Washes were performed by
re-suspending cells in 15 mL of PBS and centrifuging at 456 xg for four minutes
at 4°C in either an Allegra 6R or Allegra X15R centrifuge (Beckman Coulter).
Supernatant was then removed from the cell pellets by aspiration, and the wash
was repeated once more before performing the next experimental step.
Ammonium-chloride-potassium (ACK) lysis buffer was prepared in-house and
added to cells to lyse red blood cells when necessary. The volume of ACK lysis
buffer used and incubation time at room temperature varied depending on the
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number of leukocytes and density of red blood cells. Splenocytes were typically
incubated in three mL of ACK lysis buffer for three minutes to successfully
remove red blood cells. Cells were promptly washed with PBS following ACK
lysis buffer incubation to prevent leukocyte death.
2.2.2 Cell culture
Cells were cultured in complete Roswell Park Memorial Institute (cRPMI)
medium, which consisted of RPMI 1640 (Gibco) supplemented with 10% fetal
bovine serum (FBS; heat-inactivated and 0.3 µm-filtered, Wisent Bioproducts), 2
mM glutaMAX, 100 Units/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES,
minimum essential medium non-essential amino acids, and 1mM sodium
pyruvate (Gibco).
DC2.4 cells are immortalized dendritic cells derived from C57BL/6 mice that are
capable of phagocytosing and presenting exogenous antigens on MHC class I
and II molecules 164. DC2.4 cells were kindly provided to us by Dr. Kenneth Rock
(University of Massachusetts Medical Centre, Worcester, MA). Cells were
cultured at 37°C in 6% CO2 in cRPMI and passaged approximately every two
days when they reached confluence. Cells were washed twice before seeding
one hundredth of the recovered cells into a new 75 cm 2 flask.
2.2.3 Reagents
The MAIT cell ligand, 5-OP-RU, was generated by combining the unstable
riboflavin precursor 5-A-RU with methylglyoxal (Sigma) in dimethyl sulfoxide
(DMSO; Sigma) 165. 5-A-RU was kindly provided to us by Dr. Olivier Lantz

165.

5-

OP-RU was stored at -80°C until used. To stimulate the MAIT cell TCR in vivo,
mice were injected with 10 nmol of 5-OP-RU in PBS intraperitoneally (i.p.).
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Recombinant mouse IL-12 p70 (PeproTech) and IL-18/IL-1F4 (R&D Systems)
were resuspended in PBS and stored at -80°C. Cells were stimulated in vitro with
10 ng/mL of IL-12 and 100 ng/mL of IL-18.
TLR3 and TLR7 agonists, low molecular weight polyinosinic-polycytidylic acid
[poly(I:C)] and Imiquimod, respectively, were purchased and re-constituted in
sterile water (Invivogen). Mice received 50 µg of each agonist in PBS i.p., as has
been done previously 166,167.
2.3. MOUSE CELL ISOLATION
2.3.1 Splenic cell isolation
Following cervical dislocation, spleens were removed and promptly homogenized
in cold PBS using a glass homogenizer. Cells were pelleted by standard
centrifugation and then exposed to ACK lysis buffer to remove red blood cells.
The splenocytes were washed, re-suspended in cold PBS, and filtered over a 70
µm filter to create a single cell preparation.
2.3.2 Leukocyte isolation from the peritoneal cavity
Once euthanized, mice were placed on their backs, sprayed with 70% ethanol,
and their abdomens were massaged to release any free peritoneal exudate cells
(PECs). A small incision was made in the abdominal skin, which was used to tear
open the skin and expose the peritoneal membrane. A dulled 18.5 Gauge needle
on a 10 mL syringe filled with PBS was gently inserted through the membrane
and into the peritoneal cavity. The PBS was pushed into the peritoneal cavity to
expand it and then the PBS, which now contained the PECs, was aspirated back
into the syringe. Once the needle was removed from the peritoneal cavity, the
peritoneal membrane was cut open and the needle was used to collect any
remaining PBS. The PECs were pelleted by standard centrifugation and then
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briefly exposed to ACK lysis buffer if necessary. ACK lysis buffer was removed by
standard washing and the PECs were re-suspended at the desired concentration.
2.3.3 Leukocyte isolation from lungs
Lungs were excised from euthanized mice while still attached to the heart. In a
large petri dish, a 10 mL syringe filled with PBS attached to a 25 Gauge needle
was inserted into the heart and expelled to flush residual blood out of the lungs.
The heart and excess tissue were cut from the lungs, and both lungs were then
placed in PBS and cut into fine pieces with scissors. Each pair of perfused lungs
was placed in 4 mL of collagenase type IV solution (Sigma, 0.5 mg/mL in RPMI
1640) and left to continuously rotate at a fast pace in an incubator for one hour.
Following incubation, a 10 mL syringe plunger was used to push the lung
homogenate through a 70 µm filter. Lung leukocytes were washed, exposed to
ACK lysis buffer and washed again to obtain a single cell preparation.
2.3.4 Liver mononuclear cell isolation
Following euthanization, the liver was excised and promptly homogenized in cold
PBS in a glass homogenizer. The homogenized liver was washed and then resuspended in 25 mL of 33.75% Percoll solution in PBS (GE Healthcare). The
cells were centrifuged at 700 xg for 12 minutes at 20°C without brake to pellet
non-parenchymal cells, leaving parenchymal cells floating on top of the
supernatant. The supernatant and parenchymal cells were removed, and the
remaining cells were washed. Cells were exposed to ACK lysis buffer to remove
red blood cells and then washed before being re-suspended in PBS for
downstream analysis.
2.4. IAV INOCULATIONS
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All IAV strains were previously propagated in the laboratory in 10 day-old
embryonated chicken eggs, filter-sterilized and stored at -80°C until use

168.

Viral

infectious titers were also previously determined with a TCID 50 (median tissue
culture infectious dose) assay using MDCK cells

168.

Two different mouse-

adapted IAV strains were used, namely PR8 (Puerto Rico/8/1934/H1N1) and the
X31 reassortant (H3N2). PR8 and X31 have identical internal proteins but have
different surface HAs and NAs

169.

Three models of IAV inoculation were utilized: vaccine, recall and infection. To
mimic vaccination, mice received a 450 µL i.p. injection of PR8 mixed 1:1 with
PBS (>25,000 TCID50). IAV is unable to replicate and produce an infection via
this unnatural route of administration, as the peritoneal cavity lacks the enzymes
required to release new virions 170. However, IAV can still replicate its RNA
genome and translate its proteins in some cell types, such as dendritic cells

171.

Therefore, the mice still mount an immune response against the virus, making
this a good IAV vaccination model 170. The systemic and local anti-IAV CD8+ T
cell responses, in the spleen and PECs respectively, were evaluated seven days
post-injection when the responses were at their peaks

172.

Similar to influenza

vaccination in humans, mice can also be vaccinated with live IAV via the
intramuscular route

170.

However, the i.p. route is preferred due to the difficulty

and risks associated with intramuscular injections

173.

Furthermore, both

intramuscular and intraperitoneal live IAV delivery have been shown to produce
equivalent anti-IAV CD8+ T cell responses 170.
To model a recall response, mice received the same PR8 vaccination followed 30
days later by an i.p. vaccine “boost” with the X31 strain (>3,000 TCID 50). Antigenspecific CD8+ T cell responses were evaluated in the spleens and PECs seven
days later (day 37) 174. Because of the difference in envelope proteins, X31 is not
neutralized by the anti-PR8 antibodies; however, the immune system is reexposed to the internal proteins against which it originally developed an immune
response during PR8 exposure. This model evaluates how the memory anti-IAV
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CD8+ T cell response is shaped when challenged with a heterosubtypic IAV
strain.
Finally, to instigate a productive IAV infection, mice were anesthetized with
gaseous isoflurane in a jar and then 12.5 µL of PBS containing PR8 was
administered to each nare (25 µL total). Each mouse received a total sub-lethal
IAV dose of TCID50=1.0. Weight loss was monitored daily and mice were
euthanized if they lost more than 20% of their initial body weight. Otherwise, mice
were euthanized 10 days after inoculation to evaluate the anti-IAV CD8 + T cell
response at its peak in the spleen and lungs

109.

2.5. CYTOFLUORIMETRIC ANALYSES
2.5.1 Data collection and analysis
Flow cytometry data was collected on a FACSCanto II using the FACSDiva
software version 6 (Becton Dickinson). Compensation was performed where
appropriate using OneComp and green fluorescent protein (GFP) BrightComp
eBeads (ThermoFisher) and calculated by the FACSDiva software. Since B6CAST and MR1 KO mice expressed a RORγt-GFP reporter, GFP was
compensated for in all experiments that used these mice. Flow cytometry data
was analyzed in FlowJo versions 7 and 10 (FlowJo). Total cell numbers were
calculated by multiplying each gating proportion with the total number of cells
isolated from a given tissue, as counted on a haematocytometer prior to cell
staining, following collection of a standardized number of events on the flow
cytometer 175.
2.5.2 General surface staining protocol
For standard cell surface staining, one to two million debris-free cells were
pipetted into either 5 mL flow cytometry tubes or 96-well plates and washed twice
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with PBS. To wash, cells in flow tubes were re-suspended in two mL of PBS and
centrifuged at 456 xg for four minutes at 4°C. Alternatively, cells in 96-well plates
were re-suspended in 150 µL of PBS and centrifuged at 1026 xg for three
minutes at 4°C. Supernatant from the 2.4G2 hybridoma was used as Fc
(fragment crystallizable region) block in all staining protocols (ATCC). The 2.4G2
B cell hybridoma produces monoclonal IgG antibodies that block FcRγII/III
(CD16/CD32) 176. Twenty µL of Fc block was added to each tube/well and cells
were placed at 4°C for 5-10 minutes in the dark to prevent non-specific Fcγ
receptor-mediated antibody binding. Antibody cocktails (using amounts as shown
in Table 1) in PBS were added to each tube/well to bring the total staining volume
to 100 µL before incubation at 4°C for 20 minutes in the dark. Cells were then
washed twice with PBS, re-suspended at a concentration of 10-20 million cells
per mL, and the results were read on a flow cytometer.

39
µg per

Commonly used

test

fluorophore

Invitrogen

0.1

Alexa fluor 700

M1/70

Invitrogen

0.05

Alexa fluor 700

CD11c

N418

Invitrogen

0.05

PE-efluor 610

CD3

145-2C11

eBioscience

0.1

PE-Cy7

CD4

GK1.5

eBioscience

0.1

Alexa fluor 700

CD8

53-6.7

Invitrogen

0.05

APC

F4/80

BM8

eBioscience

0.05

APC

γδTCR

eBioGL3

eBioscience

0.25

PE

Granzyme B

NGZB

Invitrogen

0.06

PerCP-efluor 710

IFNγ

XMG1.2

Invitrogen

0.05

PE or APC

IL-17

eBio17B7

Invitrogen

0.1

PE-efluor 610

IL-2

JES6-5H4

Invitrogen

0.1

PE-Cy 7

NK1.1

PK136

eBioscience

0.12

PE

TCRβ

H57-597

Invitrogen

0.1

PE-Cy 7

TNFα

MP6-XT22

Invitrogen

0.1

PE-efluor 610

Target

Clone

Manufacturer

B220 (CD45R)

RA3-6B2

CD11b

Table 1: Fluorophore-labeled anti-mouse antibodies.
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2.5.3 Tetramer staining
Biotinylated antigen presenting molecules loaded with a specific peptide
(monomers) are tetramerized with fluorescently-labelled streptavidin to create
protein complexes that very specifically detect antigen-specific T cells. Tetramers
tend to be more finicky than regular surface stains, so modifications to the
standard surface staining protocol (section 2.5.2) are noted here. MHC class I
tetramers (H2-Db) were obtained from the National Institutes of Health (NIH)
Tetramer Core Facility (Emory University, Atlanta, GA) loaded with either purified
PA224-233 or NP366-374. Cells were stained with PE-conjugated tetramer at a dilution
of 1:200 in PBS + 5% FBS for 30 minutes at 4°C in the dark. An APC-conjugated
anti-CD8α monoclonal antibody co-stain was then added and cells were
incubated for another 20 minutes at 4°C in the dark (sample gating shown in
Figure 3). To identify MAIT cells in mice, MR1 tetramers loaded with 5-OP-RU or
6-FP were obtained from the NIH Tetramer Core Facility or monomers for inhouse tetramerization were kindly provided by Dr. Alexandra Corbett (Doherty
Institute, Melbourne, Australia)

177.

MR1 tetramers loaded with 5-OP-RU will bind

the MAIT cell TCR and identify MAIT cells (discussed in section 1.4.4) 3. 6-FP is a
folic acid (vitamin B9) metabolite that binds to MR1 and stabilizes its surface
expression, but the MAIT cell TCR does not bind to MR1 when it presents 6-FP 4.
MR1 tetramers loaded with 6-FP were therefore used as a negative staining
control. Cells were co-stained with MR1 tetramer-PE (1:400), B220-Alexa fluor
700 and TCRβ-PE-Cy7 for 30 minutes at room temperature in PBS + 2% FBS in
the dark (sample gating shown in Figure 4). B220-Alexa fluor 700, which primarily
identifies B cells, was included as a dump channel to reduce the detection of nonspecific MR1 tetramer binding. Finally, PE-conjugated CD1d tetramers loaded
with PBS-57, a stable iNKT cell agonist 178, were obtained from the NIH Tetramer
Core Facility to stain for iNKT cell frequencies. These cells were identified by flow
cytometry in a manner similar to MAIT cell identification.

SSC-W

FSC-W
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Figure 3: MHC class I tetramers. Lymphocytes were gated on and doublets
were excluded before identifying the frequency of tetramer+ cells out of CD8+
cells.

SSC-W

FSC-W
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Figure 4: MR1 tetramers. Lymphocytes were identified, doublets and B220 +
cells were excluded, and then the frequency of MR1 tetramer + cells out of TCRβ+
cells was identified. MR1 tetramer(5-OP-RU) gating was based on MR1
tetramer(6-FP) control stains. As expected, MR1 tetramer(5-OP-RU) did not
detect MAIT cells in MR1 KO mice.
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2.5.4 Intracellular cytokine staining
If cells were receiving an intracellular cytokine stain (ICS), following surface
and/or tetramer staining, cells were fixed in 1% paraformaldehyde (Sigma) at
room temperature for 15 minutes in the dark. Once the cells had been washed
twice, the intracellular antibody cocktail, containing 0.1% saponin (Sigma) to
permeabilize the cells, was applied in a staining volume of 50 µL (see Table 1 for
amounts of antibodies used). Plates were then wrapped in parafilm and tin foil for
incubation at 4°C in the dark for a minimum of one hour or overnight. Cells were
then washed twice and results were collected on a flow cytometer.
2.5.5 ICS to detect antigen-specific CD8+ T cells
A commonly used method to detect antigen-specific CD8+ T cells is to briefly
stimulate bulk leukocytes with immunogenic MHC class I-restricted peptides and
perform CD8+IFNγ+ ICS. In this specific assay, CD8+ T cells that are specific for
the stimulating peptide generate IFNγ in response to TCR stimulation with the
peptide:MHC class I complex, accurately representing the extent of clonal
expansion 179. To perform this assay, leukocytes isolated from mice previously
exposed to IAV were plated in 200 µL of cRPMI at a concentration of 10 or 20
million cells per mL. Immunogenic peptides (Table 2)

180

were added to the cells

at a concentration of 500 nM and were incubated at 37°C in 6% CO2 for five
hours. Purified peptides (>95%) were kindly provided to us by Dr. Jack Bennink
and Dr. Jonathan Yewdell and stored at -30°C in DMSO (National Institutes of
Health, Bethesda, MD). The peptides were purified by high-performance liquid
chromatography and analyzed by mass spectrometry at the National Institutes of
Health 181. In the final three hours of the incubation period, Brefeldin A (Sigma)
was added to each well at a concentration of 10 µg/mL so that any cytokines
produced in response to peptide stimulation were retained within the cells.
Following incubation, cells were stained for surface CD8 expression and
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intracellular IFNγ (as described in sections 2.5.2 and 2.5.4; sample gating shown
in Figure 5).
To evaluate IAV-specific CD8+ T cell responses, cells were stimulated with seven
known IAV peptides, two control conditions and IAV-exposed DC2.4 cells. The
control conditions included a “nil”/no peptide stimulation and stimulation with an
immunodominant peptide derived from a virus to which the mice had never been
exposed and therefore, had no detectable antigen-specific CD8 + T cells [e.g.
Herpes simplex virus 1 (HSV-1) or lymphocytic choriomeningitis
mammarenavirus (LCMV)] 180. In the final condition, confluent DC2.4 dendritic
cells were harvested and incubated with PR8 (>50,000 TCID 50) at 37°C and 6%
CO2 while continuously and quickly rotating for six hours in cRPMI. These cells
were then plated with isolated immune cells in place of a peptide. These DCs
theoretically presented all IAV-derived peptides on MHC class I molecules;
however, some more efficiently than others, according to the principle of
immunodominance. During flow cytometric data analysis, each set of stimulations
per animal/tissue received the same gates. The IFNγ+ gate was set based on the
nil condition and the frequency of IFNγ+ cells within the CD8+ cell population
detected in the nil condition was subtracted out of all the other stimulation
conditions to account for the minimal background in this assay.
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Peptide

MHC

Amino acid

(H2-)

sequence

Acidic polymerase

Db

SSLENFRAYV

Nucleoprotein

Db

ASNENMETM

Db

LSLRNPILV

Basic polymerase protein 1

Kb

SSYRRPVGI

IAV

Matrix 1 protein

Kb

MGLIYNRM

NS2114-121

IAV

Non-structural protein 2

Kb

RTFSFQLI

PB2198-206

IAV

Basic polymerase protein 2

Kb

ISPLMVAYM

Gb498-505

HSV-1

Glycoprotein B

Kb

SSIEFARL

GP33-41

LCMV

Glycoprotein

Db

KAVYNFATC

Virus

Origin protein

PA224-233

IAV

NP366-374

IAV

PB1-F262-70

IAV

PB1703-711

IAV

M1128-135

name

Basic polymerase protein 1 –
frame 2

Table 2: Immunogenic peptides used in these investigations.

SSC-A
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FSC-A

SSC-H

Figure 5: Gating strategy to determine the frequency of antigen-specific
CD8+ T cells. After gating on live cells and excluding doublets, the percentage of
IFNγ+ cells out of CD8+ cells was identified. The no peptide (nil) control
stimulation should yield negligible to no levels of IFNγ production by CD8 + T cells,
whereas stimulation with an immunodominant IAV peptide (PA 224) causes many
CD8+ T cells to produce IFNγ, demonstrating their specificity for this peptide.
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In some experiments, the polyfunctionality of the CD8+ T cell response was also
assessed (discussed in section 1.3.3). During the standard CD8 +IFNγ+ ICS
protocol, monoclonal antibodies to TNFα and IL-2 were added during intracellular
staining. Boolean gating was used to determine the abundance of polyfunctional
antigen-specific CD8+ T cells (Figure 6) 182. Boolean gating is a function of
FlowJo version 10 that calculates how many events fall into multiple co-selected
gates. In this case, IFNγ+, TNFα+ and IL-2+ events were independently identified
as frequencies of CD8+ events and then the Boolean gating function calculated
the frequency of events within the CD8+ population that were positive for multiple
cytokines.
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Figure 6: Polyfunctional CD8+ T cell responses. Following gating on CD8+ T
cells as shown in Figure 5, IFNγ+, TNFα+ and IL-2+ populations were individually
identified based on the nil condition, and as a frequency of CD8 + T cells. Boolean
gating (FlowJo version 10) was utilized to calculate the frequency of IFNγ +TNFα+
and IFNγ+TNFα+IL-2+ cells within the CD8+ cell population.

49
2.6 IN VIVO KILLING ASSAY
Isolated splenocytes from naïve C57BL/6 donor mice were used to prepare
“target cells”. Equal proportions of target cells were incubated with 1µM of an
MHC class I-restricted peptide (Table 2): either an irrelevant peptide from LCMV
(GP33) or the immunodominant IAV peptide of the vaccine model (PA 224). After
one hour of peptide pulsing at 37°C and 6% CO2, target cells were labelled with
carboxyfluorescein succinimidyl ester (CFSE). CFSE binds to amines on the
surface and inside of all cells it encounters. Target cells labelled with the
irrelevant peptide were stained with a low concentration of CFSE (0.02 µM,
“IRRLO”) and the IAV peptide-labelled target cells were stained with a high
concentration of CFSE (0.2 µM, “IAVHI”), which subsequently allowed for
identification of each distinct population by flow cytometry. CFSE staining was
stopped through exposure to FBS, and IRRLO and IAVHI target cells were mixed
in equal proportions. MR1 KO and B6-CAST mice that had been previously
vaccinated with IAV seven days prior (“vaccinated”), as well as control naïve mice
(“naïve”), received 10-20 million target cells by intravenous (i.v.) injection. Thirty
minutes later, mice were euthanized and splenocytes were collected to assess
the number of recovered target cells by flow cytometry. Percent specific killing
was calculated based on the following cell population numbers: 100 –
[(vaccinated IAVHI/vaccinated IRRLO)/(naive IAVHI/naive IRRLO)] × 100.
2.7 STATISTICAL ANALYSES
Graphs and statistical results were generated by Prism version 5 (Graphpad).
Data were plotted as mean ± standard error of the mean. Statistics were
calculated as appropriate, using unpaired t-tests, Mann Whitney tests, one- or
two-way ANOVAs with Bonferroni post-tests, Kruskal-Wallis tests with Dunns
post-tests, or the log-rank test. In most cases, parametric tests were utilized,
based on the assumption that data were normally distributed around a biological
mean. When comparisons were made amongst tetramer-stained populations
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pooled from multiple experiments, non-parametric tests were used due to the
variation in lots and sources of tetramers, which gave differential staining results.
In these cases, our reagents precluded the assumption of biological normality.
Open brackets indicate statistical results from multiple comparisons (ꟷ), while
closed brackets indicate statistical results from the comparison between the two
identified numbers (┌┐). Statistical significance is indicated where appropriate,
where * = p<0.05, ** = p<0.01, and *** = p<0.001.
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CHAPTER 3: RESULTS
3.1 The frequencies of major immune cell subsets are comparable between
naïve MR1 KO and B6-CAST mice

I primarily used MR1 KO and B6-CAST mice throughout my studies because of
the lack of MAIT cells in the former and the abundance of MAIT cells in the latter
148.

However, before evaluating the impact of MAIT cells on other immune cell

subsets, I wanted to determine whether there were baseline variations in the
frequencies of these populations in these mouse strains. I stained for multiple
immune cell types in naïve WT B6, MR1 KO and B6-CAST mouse lungs, which
tend to harbour the largest frequency of MAIT cells in mice 1. I found that MAIT
cell frequency varied significantly between B6-CAST and MR1 KO mice in the
lungs (Figure 7). Similar findings were obtained when splenocytes were used
(data not shown). Interestingly, there did appear to be a significant difference in
iNKT cell frequencies amongst the three mouse strains tested; however, post-test
comparative analyses did not find a significant difference between any single pair
of mouse strains (Figure 7D). All other immune cell subsets did not vary
significantly amongst strains (p>0.12).
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Figure 7: MR1 KO mice lack MAIT cells relative to B6-CAST mice. Lung
leukocytes from male and female naïve WT B6, MR1 KO and B6-CAST mice
were stained with the indicated surface markers to assess each mouse strain’s
baseline frequencies of multiple immune cell types. CD3 + T cells (A), B220+ cells
(G), NK1.1+ NK cells (CD3-, H), CD11b+ polymorphonuclear cells (CD3-F4/80NK1.1-, I), CD11c+ dendritic cells (CD3-F4/80-NK1.1-, J), and F4/80+
macrophages (CD3-, K) are shown as frequencies of singlet cells. CD4+ (B),
CD8+ (C), and γδ (F) T cells are shown as frequencies of CD3 + T cells. CD1d
tetramer+ iNKT cells (B220-, D) and MR1 tetramer+ MAIT cells (B220-, E) are
shown as frequencies of TCRβ+ cells. Statistical significance was assessed by
one-way ANOVAs followed by Bonferroni post-tests to compare each pair of
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means (n=3 from 1 experiment). Apart from iNKT and MAIT cells, the frequencies
of immune cell subsets did not vary significantly amongst mouse strains (p>0.12).
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3.2. MAIT cell presence tends to enhance protection against IAV infection
I began by determining whether MR1 KO and B6-CAST mice respond to
sublethal IAV infection differently. Mice were infected with 1.0 TCID50 of PR8
intranasally (i.n.) and monitored for weight loss for 10 days (Figure 8). Mice that
lost more than 20% of their initial weight reached a humane endpoint and were
immediately euthanized. While male MR1 KO and B6-CAST mice showed no
difference in mortality (Figure 8C), female B6-CAST mice showed a strong trend
towards enhanced survival over female MR1 KO mice (p=0.064, Figure 8A). Male
mice that survived infection experienced no MAIT cell-dependent morbidity
impact (Figure 8D), while female MR1 KO survivor mice may have suffered
slightly less severe disease than B6-CAST mice (Figure 8B).
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Figure 8: MAIT cells may confer female mice with a survival advantage
during IAV challenge. MR1 KO and B6-CAST mice were challenged with 1.0
TCID50 of PR8 i.n. and monitored daily. Mice were euthanized if they lost more
than 20% of their initial weight or at the experimental endpoint on day 10. Female
and male survival (A, C, n=10 pooled from 4 independent experiments) and daily
percent weight loss, as a measure of morbidity, of survivor mice (B,D, n=5-9
pooled from 3 independent experiments) are shown. Survival statistical analyses
were performed with the log-rank test (p=0.064 [A], p=0.61 [C]).
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Mice that survived i.n. IAV infection were euthanized on day 10 and antigenspecific CD8+ T cells were enumerated amongst splenocytes and nonparenchymal lung immune cells to assess the systemic and local CD8 + T cell
responses, respectively. I first stained the immune cells with MHC class I
tetramers loaded with NP366, the IAV infection model immunodominant peptide
(as shown in Figure 10). Although quite variable, tetramer staining showed no
difference between MR1 KO and B6-CAST splenic responses (Figure 9A, C).
Preliminary data showed that MAIT cell presence may correlate with an increase
the number of NP366-specific CD8+ T cells in female lungs (Figure 9B), while the
opposite may be true in males (Figure 9D). However, these results are
preliminary and are lacking sufficient repetitions to make any conclusions at this
point in time. To assess whether MAIT cell frequency varied between male and
female B6-CAST mice, perhaps contributing to sex differences in the CD8 + T cell
responses, MR1 tetramers were used to stain for MAIT cell frequency amongst
TCRβ+ cells (Figure 9E). MAIT cell frequency differences were not observed
between male and female B6-CAST mice (Figure 9E). However again, repetitions
would be necessary before making any conclusions concerning the impact of sex
on MAIT cell frequency.

57

Figure 9: Tetramer staining following i.n. IAV challenge. Ten days following
i.n. IAV challenge, splenocytes (A, C) and lung leukocytes (B, D) from surviving
female (A-B) and male (C-D) MR1 KO and B6-CAST mice were stained with
NP366:H-2Db tetramers. H-2Db tetramer+ cell frequency amongst CD8+ T cells is
shown. Cells from B6-CAST mice were also stained with MR1 tetramers to
enumerate MAIT cell frequency amongst TCRβ+ cells (E). Statistical comparisons
were performed using the Mann Whitney test (n=1-5 pooled from 1-2 individual
experiments; p=0.63 [A], p=0.56 [C], p=0.11 [D], p=0.27 [E spleen]). Statistical
comparisons were not made in B or E (lungs) due to the lack of a minimum of
three data points per group.
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While MHC class I tetramers identify the frequency of antigen-specific CD8 + T
cells, they provide no information with respect to their functionality. So, I
assessed the functional anti-IAV CD8+ T cell response through ex vivo
stimulation of splenocytes and non-parenchymal lung leukocytes with IAV
peptides or IAV-exposed DCs (Figure 10). While stimulation with individual IAV
peptides gave an indication of the size of each responsive clonal CD8 + T cell
population, stimulation with IAV-exposed DCs gave an estimate of the overall
anti-IAV CD8+ T cell response because of the DCs’ capability to process and
present many IAV-derived antigens. Antigen-specific CD8 + T cells were identified
as cells that produced IFNγ in response to stimulation. Systemic CD8 + T cell
responses in both males and females showed a trend towards enhancement in
the presence of MAIT cells, with B6-CAST mice developing 30-70% more antiIAV CD8+ T cells than MR1 KO mice (Figure 10A-B, D-E). At the site of infection
in the lungs, there was a trend that female B6-CAST mice had more antigenspecific CD8+ T cells than did their MR1 KO counterparts (Figure 10C), while the
opposite trend was observed in male mice (Figure 10F). Comparisons of absolute
numbers of antigen-specific CD8+ T cells between MR1 KO and B6-CAST mice
showed the same trends as frequencies did throughout this thesis and are
therefore not shown.
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Figure 10: The presence of MAIT cells tends to enhance the systemic
antigen-specific CD8+ T cell response to IAV challenge. Ten days following
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i.n. IAV challenge, surviving MR1 KO and B6-CAST mice were euthanized.
Isolated splenocytes were stimulated with immunogenic peptides (A, D) or IAVexposed DCs (B, E), and lung leukocytes were stimulated with immunogenic IAV
peptides (C, F) for five hours prior to CD8+IFNγ+ ICS. The frequencies of IFNγ+
cells amongst CD8+ T cells are plotted. Unpaired t-tests were used to compare
the CD8+ T cell responses between MR1 KO and B6-CAST mice under each
separate stimulus condition (n=3-8 pooled from 3 independent experiments;
p=0.12-0.59 [A], p=0.097 [B], p=0.20-0.26 [C], p=0.063-0.45 [D], p=0.32-0.35 [F]).
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3.3 MAIT cell abundance promotes the CD8 + T cell response to IAV
vaccination
I next evaluated the impact of MAIT cell presence on the antigen-specific CD8 + T
cell response that develops following vaccination. MR1 KO and B6-CAST mice
were vaccinated with PR8 i.p. This unnatural route of administration does not
produce an active IAV infection, but still provides the immune system with the
opportunity to detect non-productive IAV replication and mount an immune
response against the virus 170,171. Seven days following PR8 injection, mice were
euthanized to evaluate the systemic and local CD8+ T cell responses in the
spleens and PECs, respectively. I began by staining immune cells with MHC
class I tetramers loaded with either the PA224 or NP366 peptide. This method of
clonal CD8+ T cell detection showed that MAIT cell presence had no influence in
female mice (Figure 11A), but appeared to negatively impact antigen-specific
CD8+ T cell expansion in male mice (Figure 11B). Splenic MAIT cell frequencies
in B6-CAST mice again did not vary between the sexes at the experimental
endpoint (Figure 11C).
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Figure 11: B6-CAST mice develop equal or less IAV tetramer + antigenspecific CD8+ T cells in response to vaccination. Splenocytes isolated from
female (A) or male (B) MR1 KO and B6-CAST mice seven days following PR8
vaccination were stained with MHC class I tetramers loaded with either PA 224 or
NP366. The frequencies of MHC class I tetramer+ cells amongst CD8+ cells are
shown. B6-CAST splenocytes were also stained with MR1 tetramers to assess
MAIT cell frequencies amongst TCRβ+ cells in male and female mice (C).
Statistical significance was calculated with the Mann Whitney test (n=4-7 pooled
from 2-3 independent experiments; p=0.80, 0.26 [A], p=0.030, 0.24 [B], p=0.76
[C])
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To assess the amount of functional antigen-specific CD8+ T cells following
vaccination, splenocytes were exposed to immunogenic IAV peptides (Figure
12A) or IAV-exposed DCs (Figure 12B) for five hours before identifying IFNγproducing IAV-specific CD8+ T cells. No differences in the CD8+ T cell responses
were detected between male MR1 KO and B6-CAST mice. However, female B6CAST mice appeared to generate at least 30% more antigen-specific CD8 + T
cells than female MR1 KO mice did. I also assessed the polyfunctionality of
female antigen-specific CD8+ T cells by evaluating their concurrent production of
IFNγ, TNFα, and/or IL-2. CD8+ T cells that produce a variety of cytokines have an
enhanced functionality and ability to contribute to anti-IAV immunity

116.

The

PA224 response was more polyfunctional than the NP 366 response in both mouse
strains, as indicated by the greater frequency of IFNγ+TNFα+ and IFNγ+TNFα+IL2+ CD8+ T cells following peptide stimulation (Figure 12C). Despite a trend that
B6-CAST mice had slightly more polyfunctional antigen-specific CD8 + T cells
than MR1 KO mice, this difference was not statistically significant. When
evaluating the antigen-specific CD8+ T cell response amongst pooled PECs, I did
not notice any differences between MR1 KO and B6-CAST mice (data not
shown).
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Figure 12: Female B6-CAST mice tend to develop a larger anti-IAV CD8 + T
cell response than MR1 KO mice following vaccination. MR1 KO and B6CAST mice were vaccinated i.p. with PR8 and euthanized seven days later.
Isolated splenocytes were stimulated with immunogenic IAV peptides (A) or IAVexposed DCs (B) for five hours before staining for surface CD8 and intracellular
IFNγ (n=10-13 pooled from 5 independent experiments). Some female
splenocytes received additional TNFα and IL-2 intracellular stains to assess the
polyfunctionality of PA224 and NP366-directed CD8+ T cell responses (C, n=7
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pooled from 3 independent experiments). The frequencies of cytokine(s) + cells
amongst CD8+ cells are shown. Unpaired t-tests were used to compare MR1 KO
and B6-CAST responses to each stimulus (p=0.021-0.55 [A female], p=0.39-0.97
[A male], p=0.14 [B female], p=0.39 [B male], p=0.17-0.54 [C PA 224], p=0.13-0.22
[C NP366]).
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Finally, I evaluated the ultimate function of CD8 + T cells, namely their ability to kill
target cells in vivo. Seven days following vaccination, MR1 KO and B6-CAST
mice were injected i.v. with CFSE-labelled target cells, half of which were labelled
with an “irrelevant” peptide from a virus to which the mice had never been
exposed and a low dose of CFSE, while the other half was labelled with the
immunodominant PA224 peptide (as shown in Figure 12) and a high dose of
CFSE. Thirty minutes following injection, mice were euthanized and target cells
were recovered from the spleens. Interestingly, regardless of mouse sex, there
were significantly less PA224-pulsed target cells recovered from B6-CAST spleens
relative to MR1 KO spleens (Figure 13). This suggested that the B6-CAST PA 224specific CD8+ T cell population was more effective at killing target cells than the
population in MR1 KO mice.
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Figure 13: PA224-targeted cytotoxicity is greater in vaccinated B6-CAST
mice than in vaccinated MR1 KO mice. Naïve mice, as well as male and
female MR1 KO and B6-CAST mice that had been vaccinated with PR8 i.p.
seven days earlier, were injected i.v. with CFSE-labelled target cells. Half of the
target cells were labelled with a low dose of CFSE and an irrelevant peptide
(GP33 from LCMV; “irr”), or a high dose of CFSE and the immunodominant IAV
peptide (“PA224”). Thirty minutes following injection, mice were euthanized and
the splenocytes were evaluated by flow cytometry (A) to assess the number of
recovered target cells and to calculate percent specific killing (B) with the
following formula: 100 – [(vaccinated PA224/vaccinated irr)/(naïve PA224/naïve irr)]
× 100. An unpaired t-test was used to calculate the statistically significant
difference between MR1 KO and B6-CAST mice (n=5 pooled from 2 independent
experiments).
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3.4 MAIT cell presence does not impact recall CD8 + T cell responses to IAV
epitopes
Finally, I evaluated the impact of MAIT cell abundance on the anti-IAV CD8 + T
cell response in a recall model. Mice were injected i.p. with PR8 and received a
“boosting” X31 vaccination 30 days later. They were euthanized seven days later
(day 37) to evaluate the antigen-specific CD8+ T cell response. While both PR8
and X31 share the same internal proteins against which the anti-IAV CD8 + T cell
response is directed, they have different surface HA and NA proteins

169.

This

prevents X31 neutralization by antibodies that were developed in response to
PR8 challenge, which would otherwise compromise the X31 dose received by
each mouse. In both female and male mice, NP 366 became the immunodominant
peptide, as was expected during the recall response

183,184.

However, MAIT cell

presence did not alter the results of NP366-loaded MHC class I tetramer staining
(Figure 14A-B) or CD8+IFNγ+ ICS (Figure 14C-D) experiments. Similarly,
splenocyte stimulation with IAV-exposed DCs elicited similar numbers of
CD8+IFNγ+ cells in MR1 KO and B6-CAST mice (data not shown). PECs were
collected and pooled to evaluate the local CD8+ T cell response and showed no
difference between MR1 KO and B6-CAST mice (data not shown).
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Figure 14: MAIT cells do not impact the IAV recall response. MR1 KO and
B6-CAST mice were vaccinated with PR8, boosted with X31 i.p. 30 days later,
and euthanized seven days later to evaluate the splenic antigen-specific CD8 + T
cell response. MHC class I (NP366) tetramer staining (A-B, n=4-5 pooled from 2
independent experiments) and CD8+IFNγ+ ICS (C-D, n=7 pooled from 3-4
independent experiments) evaluated the antigen-specific CD8 + T cell responses
in female (A, C) and male (B, D) MR1 KO and B6-CAST mice. MR1 KO and B6CAST responses to each stimulus condition were compared with Mann Whitney
tests (A-B) or unpaired t-tests (C-D) (p=0.22 [A], p=0.89 [B], p=0.15-0.63 [C],
p=0.21-1.00 [D]).
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3.5 Concurrent IAV exposure and MAIT cell TCR stimulation does not
enhance anti-IAV CD8+ T cell activity but does induce MAIT cell
accumulation in the PECs
Leading up to this point, MAIT cell presence appeared to slightly enhance antiIAV CD8+ T cell activity in infection and vaccination IAV models. I hypothesized
that optimizing MAIT cell activation through concurrent IAV administration (TCRindependent stimulation) and MAIT cell TCR stimulation with 5-OP-RU would
enhance CD8+ T cell activity to a greater degree

158.

5-OP-RU is a riboflavin

biosynthesis metabolite of microbial origin that binds to MR1 and is the most
potent activating MAIT cell ligand currently known 4. To determine an appropriate
in vivo 5-OP-RU dose, B6-CAST mice were injected with 1, 10 or 50 nmol of 5OP-RU i.p. and euthanized 18 hours later to stain for MAIT cells in various
organs. T cells downregulate their TCRs as a consequence of antigen-induced
activation, so I used MR1 tetramer staining frequency (i.e. MAIT cell TCR
expression) to assess MAIT cell activation

185.

MR1 tetramer+ cells were much

less detectable in mice that received 10 nmol (Figure 15) or 50 nmol (data not
shown) of 5-OP-RU relative to vehicle-treated mice, indicating MAIT cell
activation in response to these doses. Subsequent experiments used 10 nmol of
5-OP-RU i.p. to activate MAIT cells through their TCR.

Fold change in
MAIT cell frequency
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Figure 15: Ten nmol of 5-OP-RU induces MAIT cell TCR downregulation in
vivo. Vehicle or 10 nmol of 5-OP-RU in PBS was injected i.p. into B6-CAST
mice. Mice were euthanized 18 hours later and MAIT cell frequencies were
assessed in the spleen, lungs and liver with MR1 tetramers. To calculate fold
change, the average frequency of MAIT cells in 5-OP-RU-treated mice was
divided by the average frequency of MAIT cells in vehicle-treated mice for each
independent experiment. The experiment was repeated twice, and the plotted
fold change values are the averaged values from both experiments. The control
fold-change is the average vehicle MAIT cell frequency divided by itself, which is
equal to one (n=2 in each experiment, averages calculated and combined from 2
independent experiments).
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To test whether optimal MAIT cell activation through both TCR-independent and dependent stimulation would impact anti-IAV CD8+ T cell immunity, B6-CAST
mice were injected i.p. with IAV and vehicle or IAV and 5-OP-RU. Seven days
later, the antigen-specific CD8+ T cell responses were evaluated by CD8+IFNγ+
ICS (Figure 16). 5-OP-RU did not impact the CD8 + T cell response detected in
the splenocytes (Figure 16A-B) or pooled PECs (Figure 16C), and if anything,
tended to diminish it. However, I also used MR1 tetramers to stain for MAIT cells
in the peritoneal cavity and found local MAIT cell accumulation in response to IAV
and 5-OP-RU (Figure 16D). A statistically significant, but minimal, increase in
MAIT cell frequency was also detected in the spleens of IAV and 5-OP-RUtreated mice (data not shown).
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Figure 16: Concurrent administration of IAV and 5-OP-RU does not impact
the antigen-specific CD8+ T cell response but does cause local MAIT cell
accumulation. B6-CAST mice were injected i.p. with IAV + vehicle or IAV + 10
nmol 5-OP-RU and their splenic (A-B) and peritoneal (C) CD8 + T cell responses
were evaluated seven days later by CD8+IFNγ+ ICS (n=4-5 pooled from 2-3
independent experiments). The frequencies of IFNγ+ cells amongst CD8+ cells
are shown. MR1 tetramers were used to detect MAIT cell frequencies within the
TCRβ+ population in the pooled PECs (D). Statistics were calculated with
unpaired t-tests (A-C) or the Mann Whitney test (D) (p=0.12-0.79 [A], p=0.32-0.96
[B], p=0.28, 0.99 [C], p=0.10 [D]).
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3.6 MAIT cells accumulate in the peritoneal cavity in response to
intraperitoneal injection of IAV and 5-OP-RU
Following the intriguing observation that MAIT cells become frequent among
PECs of B6-CAST mice that were vaccinated seven days prior with IAV and 5OP-RU, I set out to investigate if each component of this vaccination strategy
alone was sufficient to induce MAIT cell accumulation. I injected B6-CAST mice
i.p. with 5-OP-RU, IAV, IAV and vehicle, or IAV and 5-OP-RU. I collected PECs
from individual mice both three (Figure 17A, C) and seven (Figure 17B, D) days
post-injection and enumerated MAIT cells with MR1 tetramers. Both 5-OP-RU
and IAV were required to induce MAIT cell accumulation. Concurrent IAV and 5OP-RU treatment alone induced a ten-fold higher frequency of MAIT cells three
days post-injection, and MAIT cells were still abundant on day seven. On day
seven, when many more PECs were recovered, absolute numbers of MAIT cells
per unit of volume were higher than on day three.
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Figure 17: Both IAV and 5-OP-RU are required to induce intraperitoneal
MAIT cell accumulation. B6-CAST mice were injected i.p. with 200 µL of 10
nmol 5-OP-RU in PBS, 450 µL of PR8 (1:1 with PBS), 500 µL of PR8 +
DMSO/Methylglyoxal vehicle in PBS, or 500 µL of PR8 + 5-OP-RU in PBS. Mice
were sacrificed three (A, C, n=6-7 pooled from 3 independent experiments) or
seven (B, D, n=8-9 pooled from 3 independent experiments) days later. MAIT cell
frequency amongst TCRβ+ cells in PECs (A, B) and number of MAIT cells per mL
of the peritoneal wash (C, D) from each individual mouse are shown. Statistical
differences were determined using the Kruskal-Wallis one-way ANOVA test and
individual comparisons were made with the Dunns post-hoc test.
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I then sought to evaluate whether MAIT cell accumulation was a phenomenon
specific to B6-CAST mice. To this end, I repeated the experiment in Figure 17 in
WT B6 mice. IAV in combination with 5-OP-RU similarly tended to induce MAIT
cell accumulation in the PECs three days post-infection (Figure 18A). WT B6
mice have less MAIT cells than B6-CAST mice, so I evaluated the relative MAIT
cell accumulation in both mouse strains by calculating MAIT cell frequency fold
change in IAV and 5-OP-RU-treated mice over IAV and vehicle-treated mice
(Figure 18B). Fold change in MAIT cell frequency was comparable in both strains
of mice.
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Figure 18: IAV + 5-OP-RU tends to induce MAIT cell accumulation in WT B6
mice. WT B6 mice were injected i.p. with 5-OP-RU, PR8, PR8 + vehicle, or PR8
+ 5-OP-RU, as in Figure 17. Mice were euthanized three days later, PECs were
collected from individual mice, and MAIT cell frequencies amongst TCRβ + cells
were assessed with MR1 tetramers (A, n=3-4 pooled from 2 independent
experiments). Fold change in MAIT cell frequency was calculated by dividing the
average MAIT cell frequency from IAV + 5-OP-RU-treated mice by the average
frequency from IAV + vehicle-treated mice for both WT B6 and B6-CAST mice (B,
2-3 experiments). Statistical differences were determined in (A) using the
Kruskal-Wallis one-way ANOVA test (p=0.077 [A]).
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3.7 Accumulated MAIT cells display a partially-activated phenotype and
readily respond to stimulation
I assessed whether IAV ± 5-OP-RU-treated mouse MAIT cells express markers
of activation. Three days (Figure 19A-B) and seven days (Figure 19C) following
injection, PECs were isolated and surface CD69, a T cell activation marker
(Figure 19B), and intracellular GzmB, IFNγ and IL-17 expression was assessed
in MAIT cells (Figure 19A, C). These intracellular molecules were chosen to
evaluate cytotoxic granule (GzmB) 8, T-bet-regulated (IFNγ) 148 and RORγtregulated (IL-17) 148 cytokine expression, which are all characteristically
expressed by activated mouse MAIT cells

8,148.

With the exception of IL-17

expression seven days post-injection (Figure 19C, no post-ANOVA significant
differences), treatment had no influence on activation marker expression. A
proportion of MAIT cells from all treatment groups expressed GzmB and CD69,
with GzmB expression typically increasing from day three to day seven.
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Figure 19: Peritoneal MAIT cells express basal levels of GzmB. B6-CAST
mice were injected i.p. with 5-OP-RU, IAV, IAV + vehicle, or IAV + 5-OP-RU and
euthanized three (A, B) or seven (C) days later. PECs were collected from each
individual mouse and stained for MAIT cells, CD69 surface expression (B), and
intracellular expression of GzmB, IFNγ and IL-17 (A, C). The frequencies of
activation marker+ cells amongst MAIT cells are plotted. Statistical differences
were determined using one-way ANOVA tests (A, C, n=3 from 1 experiment) or
the Kruskal-Wallis one-way ANOVA test (B, n=3-4 pooled from 2 independent
experiments; p=0.07-0.38 [A], p=0.43 [B], p=0.041-0.71 [C]).
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I next wanted to assess how accumulated MAIT cells responded to ex vivo
stimulation. I pooled PECs from mice injected seven days prior with IAV and
vehicle or IAV and 5-OP-RU and stimulated them for 24 hours with 5-OP-RU or
IL-12 and IL-18 (Figure 20). Stimulation did not impact MAIT cell GzmB
expression (Figure 20A). Stimulation with 5-OP-RU alone did not induce IFNγ
production; however, MAIT cells from both treatment groups produced IFNγ in
response to IL-12 and IL-18 stimulation (Figure 20B). Intriguingly, three times
more MAIT cells from mice treated with IAV and 5-OP-RU produced IFNγ than
MAIT cells from IAV and vehicle-treated mice in response to cytokine stimulation.
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Figure 20: Accumulated MAIT cells are responsive to stimulation. B6-CAST
mice were injected i.p. with IAV + vehicle or IAV + 5-OP-RU and euthanized
seven days later. PECs were collected and pooled by treatment group and sex.
Bulk PECs were stimulated with media alone (“nil”), 1 nM 5-OP-RU, or 10 ng/mL
of IL-12 and 100 ng/mL of IL-18 for 24 hours. Brefeldin A (10 µg/mL) was added
to cells for the last six hours of stimulation. Cells were stained with MR1
tetramers and intracellular stains for GzmB (A) and IFNγ (B). The frequencies of
MAIT cells expressing GzmB or IFNγ are shown. Statistical differences were
determined with the two-way ANOVA test and individual comparisons between
mouse treatments were compared with Bonferroni post-tests (n=5 pooled from 3
independent experiments; treatment p=0.13 and stimulus p=0.84 [A]).
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3.8 TLR3- and MAIT cell TCR-based stimulation induces MAIT cell
accumulation
To assess how IAV may work in concert with 5-OP-RU to synergistically cause
MAIT cell accumulation in the peritoneal cavity, I sought to determine whether
TLR agonism may also act in synergy with 5-OP-RU. IAV signals through TLR3
and 7 during natural infection

70,72.

So, I injected B6-CAST mice i.p. with a TLR7

agonist (Imiquimod) ± 5-OP-RU or a TLR3 agonist [poly(I:C)] ± 5-OP-RU, and
stained for MAIT cell frequency three days later. There was a trend for 5-OP-RU
and Imiquimod treatment to very slightly increase MAIT cell frequency in the
PECs relative to vehicle and Imiquimod treatment (Figure 21A). However,
poly(I:C) stimulation, only in combination with 5-OP-RU, did cause MAIT cell
accumulation in the peritoneal cavity (Figure 21B).
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Figure 21: TLR3 + 5-OP-RU stimulation induces MAIT cell accumulation. B6CAST mice were injected i.p. with 50 µg Imiquimod ± 10 nmol 5-OP-RU (A) or 50
µg poly(I:C) ± 10 nmol 5-OP-RU (B) in 200 µL of PBS to stimulate TLR7 and
TLR3, respectively. Mice were euthanized three days later, and PECs from
individual mice were isolated and stained for MAIT cell frequency amongst
TCRβ+ cells with MR1 tetramers. Statistical differences were determined with
unpaired t-tests (n=3 from 1 experiment; p=0.051 [A]).
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CHAPTER 4: DISCUSSION AND CONCLUSIONS
4.1 The influence of MAIT cell abundance on anti-IAV CD8 + T cell responses
My studies have indicated that MAIT cells may enhance the anti-IAV CD8 + T cell
response under some circumstances. I began by showing a trend that MAIT cell
presence reduced mortality in female mice challenged with IAV i.n. and tended to
increase the systemic antigen-specific CD8+ T cell response in male and female
mice (Figures 8-10). Recently, Wilgenburg et al. were the first to evaluate the role
of MAIT cells during viral infection in vivo 8. They showed that MAIT cells were
beneficial during IAV challenge 8. They demonstrated that in response to i.n.
infection with 100 plaque-forming units (PFUs) of PR8, WT B6 mice had
enhanced survival over MR1 KO mice. They followed the same humane endpoint
determination as I did; however, they only used adult male mice. This result
differs from mine in that they found that MAIT cell presence (at a lower level in
their WT B6 mice than would be found in B6-CAST mice) enhanced survival of
male mice, while I found no such advantage. Interestingly, among their
supplementary data, they showed no difference between WT B6 and MR1 KO
survival when challenged i.n. with 5000 PFUs of X31, which is less pathogenic
than PR8 186 . In my model, I infected mice i.n. with a TCID50 of 1.0 of PR8, which
approximates to less than 1 PFU 187. This infectious dose was sufficient to induce
morbidity in most mice, as indicated by some weight loss, without requiring
humane euthanization of the majority of the mice, as required when mice lose
more than 20% of their initial body weights. It is possible that my sublethal dose,
similar to Wilgenburg et al.’s use of the X31 virus, was not strong enough to
reveal any survival differences between male MR1 KO and B6-CAST mice. Their
data using 100 PFUs of PR8 also showed more severe weight loss in survivor
mice, with maximal weight loss approaching 20% on day nine post-infection,
while I observed maximal weight loss of less than 10% on day seven in my
survivors. It is possible that MAIT cells are not influential in male mice at relatively
low IAV infectious doses; however, I did observe that at the same dose, MAIT cell
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presence tended to be protective in female mice. This was one of the first
examples of differential MAIT cell influence between males and females that I
observed in my studies.
Wilgenburg et al. also enumerated PA224 and NP366-specific CD8+ T cells nine
days post-infection using MHC class I tetramers and reported that WT B6 mice
had more splenic tetramer+ cells than MR1 KO mice did, but detected no
differences in the lungs 8. Although not statistically significant, my splenic
CD8+IFNγ+ ICS results 10 days post-infection tended to support these
conclusions in male and female mice. However, my MHC class I tetramer
staining on the same cells showed no difference between the two strains. In
contrast to Wilgenburg et al.’s data, my CD8+IFNγ+ ICS and MHC class I tetramer
staining showed a trend that female B6-CAST mice had more antigen-specific
CD8+ T cells in their lungs than MR1 KO mice did, while the opposite trend was
observed in male mice. My lung results may differ from Wilgenburg et al.’s again
due to variation in the severity of induced illness. While Wilgenburg et al.
evaluated the CD8+ T cell population nine days post-infection when their mice
were experiencing their highest level of morbidity, I evaluated the response 10
days post-infection once the mice had most likely cleared their infections, as
suggested by the fact that their weights had returned to initial levels by this time.
Measuring the levels of antigen-specific CD8+ T cells on day seven in my model,
at the peak of mouse morbidity, would be interesting. Although it has been shown
that aberrant CD8+ T cell accumulation in the lungs may be harmful if the cells
are unable to control IAV replication

124,

my model showed that B6-CAST female

mice tended to experience a survival advantage, which may have been conferred
by a larger pool of capable antigen-specific lung CD8+ T cells which male B6CAST mice lacked.
Next, I compared systemic antigen-specific CD8 + T cell responses in MR1 KO
and B6-CAST mice seven days following i.p. PR8 vaccination (Figures 11-13). In
this model, female B6-CAST mice tended to have larger anti-IAV CD8 + T cell
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responses, as detected by staining for CD8+ T cells that produced IFNγ in
response to antigen stimulus, than female MR1 KO mice. Male B6-CAST mice
may have actually had a smaller response than MR1 KO mice as shown by MHC
class I tetramer staining. However, my in vivo killing assay suggested that both
male and female B6-CAST mice harboured a more effective PA224-targeted CD8+
T cell population than MR1 KO mice did. Finally, I detected no real difference in
the amount of polyfunctional T cells between MR1 KO and B6-CAST mice,
although I did observe that there were more polyfunctional PA 224-directed CD8+ T
cells that concurrently produced IFNγ, TNFα and IL-2 than was observed
amongst NP366-directed CD8+ T cells in both strains of mice, as has been
reported before 116.
Intriguingly, I found that MAIT cells had no impact on the IAV recall response
(Figure 14). My results therefore suggest that MAIT cells may only be influential
during the primary response to IAV. Following primary IAV exposure, antigenspecific CD8+ T cell populations contract and then re-expand once recalled

169,186.

Perhaps the CD8+ T cell clonal populations collapse into similarly sized memory
pools in both MR1 KO and B6-CAST mice. There are also significant changes in
antigen presentation between acute and recall responses

188,

so it is possible that

MAIT cells may have an important influence on antigen presentation during
primary IAV exposures, but do not influence antigen presentation to memory cells
126,128,129.

Some clear sex differences emerged during my investigations. It is already
known that males and females react differently to IAV infection and vaccination.
While human young (<20 years) and old (>80 years) males suffer increased IAVinduced morbidity than females of the same age do, women experience higher
relative morbidity in their reproductive years

189.

When mice are challenged with

IAV i.n., females experience poorer survival than males at large doses

190.

However, human 191 and mouse 190 females generate greater antibody titers than
males do in response to vaccination. Taken together, it appears that females may
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mount more inflammatory anti-IAV responses than males, which could be
overpowering and dangerous if unable to appropriately control viral infection. My
data suggests that MAIT cells behave differently in males and females, but it is
unknown how this could be regulated.
When B6-CAST mice were euthanized following IAV exposure to evaluate
antigen-specific CD8+ T cell responses, I often also assessed MAIT cell
frequency. I did not detect any difference in MAIT cell frequencies between males
and females; however, it is worth noting that I have not extensively characterized
MAIT cell frequencies in naïve mice. It is therefore possible, although unlikely,
that male and female B6-CAST mice may have differing basal levels of MAIT
cells that could influence the immune response to IAV. However, despite great
variation in humans, sex has not been shown to influence MAIT cell abundance
in the blood 192. Therefore, hormones may play a role in MAIT cell regulation.
Estradiol plays a complicated and interesting role in female immunity, with low
levels being permissive of hyper-inflammation and high levels causing Estrogen
Receptor-α (ER-α)-mediated NF-κB repression

193.

When IAV-infected

ovariectomized mice are administered estradiol, they do not develop larger
amounts of antigen-specific CD8+ T cells as detected by MHC class I tetramer
staining, relative to ovariectomized mice that do not receive exogenous estradiol
194.

However, they do develop a larger amount of reactive, IFNγ and TNFα-

producing antigen-specific CD8+ T cells as detected by ICS 194. My own
CD8+IFNγ+ ICS results showed promising trends when comparing B6-CAST and
MR1 KO female T cell responses, while MHC class I tetramers stains often did
not show the same trends. Perhaps estradiol was acting through MAIT cells to
enhance the quality of the antigen-specific CD8 + T cell response in female B6CAST mice.
Although nobody has assessed the impact of sex hormones on MAIT cells so far
to my knowledge, it has been shown that estradiol does influence iNKT cells,
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which share many similarities with MAIT cells 195. When WT B6 mice were
administered α-galactosylceramide (α-GalCer), the specific TCR agonist of iNKT
cells, significantly more IFNγ was detected in the serum of female mice than in
male mice. This difference was abrogated by ovariectomy in female mice, while
orchidectomy in male mice did not influence serum IFNγ levels. iNKT cells
express the ER-α, and exogenous estradiol administration was able to rescue the
enhanced female serum IFNγ levels in ovariectomized mice. Importantly,
estradiol also enhanced iNKT IFNγ production in response to i.v. IL-12 and IL-18
administration 195. Considering the similarities between iNKT and MAIT cells, one
may hypothesize that MAIT cells express the ER-α and that their levels of IFNγ
production in response to cytokines released during IAV infection are influenced
by estradiol in mice. Without estradiol in male mice, or without MAIT cells able to
respond to estradiol in MR1 KO mice, IFNγ levels may be reduced in these mice
in a way that restricts the expansion of reactive CD8 + T cell clones. Although not
explored as a part of this project, the impact of sex hormones on MAIT cells is a
very worthy avenue of investigation and commonly unappreciated in immunology
196.

So, the question is how might IFNγ impact the antigen-specific CD8+ T cell
response? IFNγ is not necessary for an effective CD8 + T cell response in primary
infection 197; however, it has been shown that IFNγ KO mice infected intranasally
with IAV accumulate less epitope-specific CD8+ T cells in the bronchoalveolar
lavage relative to WT mice as detected by MHC class I tetramer staining

162.

Interestingly, iNKT cell-deficient mice develop similarly sized antigen-specific
CD8+ T cell responses as compared to WT mice

163.

However, the iNKT cell-

deficient mice have a dampened functional, cytolytic CD8+ T cell response,
attributable to a lack of iNKT-induced IFNγ release. Differential levels of IFNγ in
my model may lead to less pronounced differences in CD8 + T cell populations, as
detected by CD8+IFNγ+ ICS. It is also important to note that IFNγ is important for
optimal antigen processing and presentation by MHC class I

198,199.
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MAIT cells may influence antigen presentation in a way that modulates the CD8 +
T cell response. Comparisons between MR1 KO and WT B6 mice have already
shown differences in the accumulation of macrophages and DCs in response to
viral and bacterial infections. In response to i.n. PR8 infection, Wilgenburg et al.
showed that WT B6 mice had significantly higher numbers of alveolar
macrophages than MR1 KO mice did three days post-infection 8. Another group
has shown that MR1 KO mice have significantly reduced levels of lung
inflammatory monocyte-derived DCs than WT B6 mice four and five days postinfection with Francisella tularensis live vaccine strain (LVS) 200. In this model of
intracellular bacterial lung infection, a lack of MAIT cell-dependent GM-CSF
production was responsible for reducing APC accumulation in MR1 KO mice
Although inflammatory and able to contribute to IAV-induced pathology

200.

201,

monocyte-derived DCs are required for the timely recruitment of and antigen
presentation to antigen-specific CD8+ T cells during IAV infection

202.

Finally,

human MAIT cell stimulation with 5-OP-RU has been shown to activate
monocyte-derived and plasmacytoid DCs to produce IL-12 through expression of
CD40 203. IL-12 enhances proliferation and cytolytic CD8+ T cell activity 204. Basal
levels of MAIT cell-dependent DC activation were also observed in the absence
of 5-OP-RU, suggesting that alternate methods of MAIT cell activation could
promote DC activation 203. Therefore, the absence of MAIT cells in MR1 KO mice
may restrict or delay the antigen-specific CD8+ T cell response by hindering
antigen presentation (Figure 22).
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Figure 22: MAIT cells may modulate the anti-IAV CD8+ T cell response. MAIT
cells are activated by IL-18 released in response to IAV

6–8.

In response, MAIT

cells may produce IFNγ which could enhance the activity and/or number of antiIAV CD8+ T cells 162,163, increase MHC class I presentation

198,199,

and/or induce

greater APC accumulation at the site of infection 8. MAIT cells may also enhance
antigen presentation through CD40L ligation

203

or production of GM-CSF 200.

Estradiol may also signal through ER-α in MAIT cells to increase their production
of IFNγ, as is seen in iNKT cells 195, to further enhance anti-IAV CD8+ T cell
response in females.
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One limitation of my studies was that I did not evaluate the CD8 + T cell response
at multiple timepoints following IAV administration, due to limited numbers of
mice available to me. Mice were euthanized on the traditional day of peak CD8 + T
cell expansion following IAV exposure, based on results that have been collected
from WT B6 mice in the past. It is possible that the presence or absence of MAIT
cells impacts the time course of CD8+ T cell expansion and recruitment.
Wilgenburg et al. found that five days post-i.n. PR8 infection, WT B6 mice had
significantly more non-MAIT T cells in their lungs than MR1 KO mice did, but
these investigators did not look beyond day seven 8. Another group infected WT
B6 and MR1 KO mice i.n. with Francisella tularensis LVS and found that up until
12 days post-infection, MR1 KO mice had lower amounts of pulmonary CD8 + T
cells than did WT B6 mice 161. WT B6 mouse CD8+ T cells were also more active,
as measured by expression of IFNγ, CD69, and CD44, than MR1 KO CD8 + T
cells during the early phase of infection. Therefore, it is possible that antigenspecific CD8+ T cell responses in my MR1 KO mice were delayed, but ultimately
expanded to the same levels as observed in B6-CAST mice. This delay could
also explain why I saw no difference between MR1 KO and B6-CAST mice in the
recall model, which gives the CD8+ T cell response a longer time frame to
develop. Performing a time course evaluation of antigen-specific CD8 + T cell
responses during primary IAV exposure in MR1 KO and B6-CAST mice may
show a deficit in timely T cell accumulation rather than stunted activity.
In addition to evaluating the magnitude of the antigen-specific CD8 + T cell
response, I was able to assess how each antigen-specific CD8 + T cell population
may be contributing to anti-IAV immunity. I looked at antigen-specific CD8 + T cell
responses to seven different IAV peptides with CD8+IFNγ+ ICS assays which
provided a very comprehensive assessment of the CD8+ T cell response and also
allowed us to evaluate whether MAIT cell presence or absence impacted the
immunodominance hierarchy. However, I did not observe sex, MAIT cell
presence, or MAIT cell activation to influence the IAV immunodominance
hierarchies (Figures 10, 12, 14 and 16). Any enhancement that MAIT cell
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presence tended to have on the CD8+ T cell response appeared global, although
differences were most evident when looking at the immunodominant peptides,
PA224 and NP366. In the infection model, NP366 was immunodominant over PA224
in females (p<0.01 by two-way ANOVA) while the two peptides were co-dominant
in male mice. Typically, the two peptides are co-dominant in WT B6 mice

184,186.

In response to vaccination, PA224 was dominant over NP366 (p<0.05 by two-way
ANOVA), while traditionally the PA224 and NP366 responses are co-dominant
183,184.

The recall model showed that NP366 was the dominant IAV peptide over

PA224 (p<0.01 by two-way ANOVA) as has previously been reported

183,184.

Immunodominance hierarchies are regulated by a set of intricate rules and
factors 111. It has been suggested that PA224 is presented effectively by DCs,
while NP366 is effectively presented by both DCs and non-DC APCs

188.

This

promotes NP366 to the immunodominant position during the recall response due
to a greater reliance on epithelial cell-mediated antigen presentation during reinfection than DC presentation, which is more important during the primary
response 188. Therefore, it is possible that MR1 KO and B6-CAST mice have
slightly different APC frequencies or functional attributes than WT B6 that may
have caused the differences I observed in the immunodominance hierarchies
during primary IAV exposure. More extensive immune phenotyping of these mice
relative to WT B6 mice may elucidate such possible differences.
The use of B6-CAST and MR1 KO mice was an advantage of this study. MAIT
cells are often undetectable by MR1 tetramer staining in WT B6 and BALB/c
mice, so the development of MAIT cell TCR transgenic

154

and MAIT cell adoptive

transfer mouse models 155 was a necessary step to study MAIT cell biology.
However, these models push MAIT cells through unnatural ontogeny and cause
questionable distribution. B6-CAST mice naturally develop detectable levels of
MAIT cells and are the best currently available mouse model to study MAIT cells.
However, their MAIT cell abundance is still far below that observed in humans 1.
For example, while MAIT cells may represent as many as 50% of T cells in the
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human liver, I have never observed them to exceed 3% of TCRβ + cells in the
mouse liver 1.
In addition, MR1 KO and B6-CAST mouse immunological responses were very
variable. These were congenic mouse strains that were perhaps lacking more
complete progeny homogeneity than could be expected from classically in-bred
strains, such as WT B6, which are expected to give less variable responses. To
reduce variation caused by differences in MAIT cell frequencies between mice, I
could have more optimally divided mice from the same breeder colonies equally
amongst experimental groups, as has been done previously with these mice
It is also known that husbandry has bearing over immunological responses

151.

205.

Many experiments were repeated over the course of months, during which time
mouse housing may have experienced changes in humidity, temperature, noise
levels, etc. These changes may have increased the observed variability in my
experiments.
Another advantage of my studies was that I used multiple assays to evaluate
CD8+ T cell responses. All of my assays detected antigen-specific CD8 + T cells,
which is a more valuable read-out of immunological power than bulk CD8 + T cell
detection. MHC class I tetramers loaded with either PA 224 or NP366 detected
antigen-specific CD8+ T cells based on TCR specificity. However, these tetramer
stains are not the optimal method to detect anti-IAV CD8 + T cells because (1)
they provide no information on the functionality of the clones detected and (2) the
CD8+ TCR affinity threshold for tetramer binding is higher than natural MHC class
I:peptide complex recognition, suggesting that not all antigen-specific CD8 + T
cells are detected by tetramers 206. ICS mimics a more natural method of CD8 + T
cell activation through peptide stimulation and only detects reactive CD8 + T cells
that can contribute to an immune response by producing IFNγ, TNFα, and/or IL-2.
Finally, the best method to assess the cytolytic efficiency of antigen-specific CD8 +
T cells is perhaps with the in vivo killing assay. This evaluates the ultimate
cytolytic ability of antigen-specific CD8+ T cells in their natural host environment.
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The read-out here is cytolysis, indicating that we are likely measuring the
combined efforts of multiple killing strategies (e.g. FasL, TRAIL, perforin and
granzymes). The drawback to in vivo killing assays is the optimization required in
each model. CD8+ T cells are efficient killers and regardless of the experimental
conditions, each mouse should have enough functioning antigen-specific CD8 + T
cells to eventually clear all labelled target cells. Therefore, the time allowed
following target cell injection before euthanization must be optimized to capture
differential killing efficiency before all target cells are depleted in all mice.
In this study, I focused entirely on the impact of MAIT cells on the anti-IAV CD8 +
T cell response. However, B cell responses are also important in anti-IAV
immunity. It has been shown that activated MAIT cells (TCR-dependent or
independent stimulation) increase plasmablast differentiation as well as IgA, IgG
and IgM production 207. However, B cells and their antibodies are mostly
important at preventing re-infection of IAV since their activity and abundance,
respectively, peak once the majority of viruses have already been cleared

208.

Comparison of the B cell and antibody responses between MR1 KO and B6CAST mice in the recall model would be an interesting avenue to pursue.
In my final attempt to assess the impact of MAIT cells on the anti-IAV CD8 + T cell
response, I administered IAV ± 5-OP-RU i.p. to B6-CAST mice to determine
whether optimal MAIT cell activation through concurrent TCR-independent and dependent stimulation 158 would influence the CD8+ T cell response. I ultimately
found that this vaccination had no impact on the CD8+ T cell response in males or
females (Figure 16). Previously, IAV vaccinations combined with αGalCer to
stimulate iNKT cells have shown some protective properties and enhanced CD8 +
T cell responses 209–211. These vaccines combined inactivated IAV with αGalCer
and were typically administered intranasally. Perhaps modulation of our
vaccination formula or administration route would activate MAIT cells in a way
that would benefit the anti-IAV immune response.
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Although my optimized vaccination did not influence anti-IAV CD8 + T cells in the
way that I hypothesized, I did detect a large population of MAIT cells in the PECs
seven days post-vaccination. This was the largest MAIT cell population I have
detected in mice to date, and so I decided to investigate the mechanics of this
local MAIT cell accumulation.
4.2 MAIT cell accumulation in response to IAV and 5-OP-RU
In response to concurrent IAV and 5-OP-RU i.p. administration, MAIT cells
accumulate in the peritoneal cavity. MAIT cells were frequent amongst TCRβ +
cells three days following injection (13%) and remained abundant in the
peritoneal cavity on day seven (4%) (Figure 17). Despite being more frequent on
day three, total MAIT cell numbers in the peritoneal cavity were larger on day
seven, when the total amount of cells recovered was also increased relative to
day three. These results suggest that MAIT cells are early responders amongst T
cells to infection in the peritoneal cavity.
MAIT cells also tended to accumulate in WT B6 mouse PECs in response to i.p.
IAV and 5-OP-RU administration (Figure 18). Although MAIT cell frequencies
were relatively lower (5%) three days post-immunization when compared to B6CAST mice, their fold change relative to vehicle-treated mice was a bit larger
than was typically seen in B6-CAST mice. This is exciting because it gives other
researchers the opportunity to harvest a decent sized population of mouse MAIT
cells for ex vivo experimentation. WT B6 mice are commonly used (much more
so than B6-CAST mice) and easily injected i.p.. PECs harvesting is simple and
does not require any special equipment. This method is also easier than
inoculating WT B6 i.n. with bacteria and subsequently isolating MAIT cells from
the lungs, as is currently done by other groups, to obtain sufficient MAIT cells for
adoptive transfer experiments 8,155.
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Although I am the first to show MAIT cell accumulation in the peritoneal cavity
and in response to IAV and 5-OP-RU, others have shown MAIT cell accumulation
in the lungs in response to bacterial infection. MAIT cells were first shown to
accumulate in the lungs of WT B6 mice infected i.n. with Francisella tularensis
LVS 161. They preferentially accumulated at the primary site of infection in the
lungs and expressed markers consistent with inflammatory recruitment (CCR2 +,
CXCR3+, CCR5+). Of note, this bacterial strain did express the riboflavin
biosynthesis pathway and was therefore capable of producing the precursor to 5OP-RU 161. Later, it was shown that WT B6 mice infected i.n. with Salmonella
typhimurium, which also possesses the riboflavin biosynthesis pathway, also
caused MAIT cell accumulation in the lungs in a dose-dependent manner

155.

Anti-MR1 blocking antibody prevented accumulation, albeit, incompletely. When
mice were infected with a strain of Salmonella typhimurium that lacked the
enzyme that produces the 5-OP-RU precursor, MAIT cells did not accumulate.
This illustrated the dependence of MAIT cell accumulation on 5-OP-RU presence.
While both viral and bacterial infections provide TCR-independent stimuli for
MAIT cells, bacterial infections provide a constant source of 5-OP-RU precursor,
while I only administered a limited amount of 5-OP-RU at one time point.
Increased 5-OP-RU administration and/or multiple doses may therefore cause a
significant increase in MAIT cell abundance in the peritoneal cavity. In addition,
i.n. IAV and 5-OP-RU administration may induce greater MAIT cell accumulation
in the lungs than amongst PECs, where IAV is able to replicate and produce an
active infection. It would also be interesting to see whether IAV and 5-OP-RU coadministration i.n. would be protective against IAV infection relative to IAV
administration alone.
Intriguingly, Chen et al. observed that the majority of accumulated MAIT cells in
their model expressed CD69 (80%) in the lungs 12 days after infection (relative to
about 20% in naïve mice) 155. We also stained for multiple markers of MAIT cell
activation three and seven days post-injection (Figure 19) and saw minimal levels
of MAIT cell activation in our preliminary analysis. Treatment did not impact
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GzmB, IFNγ, IL-17, or CD69 expression. We unfortunately did not include naïve
control MAIT cells, due to MAIT cells’ scarcity in naïve mice, and could therefore
not assess whether all treatments were activating MAIT cells in a similar way or
whether we were just observing homeostatic activation levels. However, the
frequency of GzmB+ MAIT cells did appear to increase in most treatment groups
from day three to day seven, suggesting that TCR-dependent or -independent
stimuli may both activate MAIT cells to a similar extent.
My preliminary data indicate that MAIT cell GzmB production may increase in
response to activation. Others have also shown GzmB upregulation as a marker
of MAIT cell activation in humans

6,7

and mice 8. One group even suggested that

GzmB should be used as an early marker of MAIT cell activation during human
IAV infection 7. It is interesting that in response to IAV, which cannot be
specifically detected by the MAIT cell TCR, MAIT cells are still producing a
cytotoxic effector molecule. However, simultaneous upregulation of the
degranulation marker, CD107a, has not been observed 7. Therefore, MAIT cells
appear to be priming themselves for cytotoxic action, should they be able to
detect bacterial ligands through their TCR.
The purpose of rapid MAIT cell accumulation and activation in response to viral
infection is unclear. Although MAIT cells can produce cytokines that have the
potential to impact other immune cells, they are unable to harness their own
cytotoxic potential if they cannot detect ligands through their TCR

157.

As long as

5-OP-RU is present, perhaps MAIT cells accumulate in response to bacterial or
viral infection indiscriminately to fight the primary bacterial infection or the
beginning of a secondary bacterial challenge. Secondary bacterial pneumonia
was the number one cause of death during the 1918 Spanish flu and is still a
common threat today 19. Given the synergy between certain viruses and bacteria
20,21,

MAIT cells may accumulate and produce GzmB in response to viral infection

to help prevent or quickly halt secondary bacterial infection. In my model, MAIT
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cells that accumulated in response to IAV and 5-OP-RU were also primed to
respond to stimulation.
In response to ex vivo stimulation with IL-12 and IL-18, MAIT cells from an
accumulated population produced significantly more IFNγ than MAIT cells from
vehicle-treated mice (Figure 20). So, although treatment had no apparent impact
on unprompted activation status (Figure 19), MAIT cells that accumulated at the
site of infection were primed to respond to stimulation. Based on the sex
differences that were observed (discussed in section 4.1), it would be interesting
to test whether male and female MAIT cells are similarly responsive to
stimulation, or whether female MAIT cells produce more IFNγ than male MAIT
cells in response to stimulation. Repeating this experiment with male and female
B6-CAST mice may provide insight as to why MAIT cells appear to differentially
impact anti-IAV CD8+ T cell responses in male and female mice.
Finally, I sought to determine whether I could induce MAIT cell accumulation
through TLR stimulation in combination with 5-OP-RU (Figure 21). Mice were
injected with TLR3 or TLR7 agonists, to mimic IAV-induced TLR activation. I
found that although TLR7 agonism did not induce MAIT cell accumulation, TLR3
agonism, again in combination with 5-OP-RU, did induce accumulation (5% of
TCRβ+ cells). The accumulated frequency of MAIT cells was about two-fold lower
than I would expect to find in IAV and 5-OP-RU-treated mice. It is possible that
providing a higher dose of agonist would increase MAIT cell accumulation, or that
other cytokine signals during natural IAV infection are important contributors to
MAIT cell accumulation. My results are supported by recent findings that i.n.
administration of 5-OP-RU with a TLR3, 4, 2/6, or 9 agonist induces MAIT cell
accumulation in the lungs of WT B6 mice

212.

To my knowledge, it is not known

whether MAIT cells express TLRs themselves or only receive signals from other
cells as a result of TLR stimulation. The synergy that is observed between TLR
stimulation and 5-OP-RU would suggest that both stimuli are working
concurrently on MAIT cells to activate them. In the future, I would also like to
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assess whether RIG-I activation, another PRR stimulated by IAV, impacts MAIT
cell accumulation and activation. RIG-I can be stimulated in vitro by poly(I:C) and
a transfection agent (LyoVec, InvivoGen, San Diego CA). To assess the impact
of RIG-I activation, we need to design an in vitro assay read-out that mimics the
MAIT cell phenotype we observe following accumulation in vivo. I am considering
using Ki67+ (a proliferation marker) or MAIT cell TCR downregulation (activation
marker) to assess in vitro MAIT cell activation. Validation of this assay will take
place in the future.
An interesting question that remains concerning MAIT cell accumulation is
whether MAIT cells are expanding in situ or are being recruited to the site of
infection. This question could be assessed with Fingolimod hydrochloride
(FTY720) administration. FTY720 is a powerful agonist of the G protein-coupled
sphingosine 1-phosphate receptor-1, which is expressed on lymphocytes

213.

It

binds with such high affinity that it induces receptor internalization. This makes
cells unresponsive to serum lipid sphingosine 1-phosphate, which signals
lymphoid cells to egress from lymphoid organs. Therefore, my experiments could
be repeated in the presence of FTY720 and if I do not observe MAIT cell
accumulation among PECs, I could conclude that MAIT cells are being recruited
to the peritoneal cavity as opposed to expanding in situ.
Since MAIT cell accumulation can be induced in the absence of IAV and since
accumulated MAIT cells are primed to respond to stimulation, I would like to
induce MAIT cell accumulation with vehicle or TLR3 agonism and 5-OP-RU and
then vaccinate mice with PR8. Then, I can assess whether an enlarged MAIT cell
population at the site of IAV challenge impacts the anti-IAV CD8 + T cell response.
If this were to enhance the antigen-specific CD8+ T cell response, MAIT cells
could be considered as an attractive adjuvant target. There is great heterogeneity
amongst MHC class I molecules in humans, making conventional CD8 + T cells
difficult to target with a single therapeutic 115. However, MR1 is a highly
evolutionarily-conserved monomorphic molecule that is capable of presenting the
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same set of ligands to the entire population of MAIT cells

3,134,139.

Therefore, all

humans possess a population of MAIT cells that can be targeted for activation
with the same reagents, giving them great clinical potential.
4.3 Summary and conclusions
I have shown a trend that MAIT cell presence correlates with the magnitude of
antigen-specific CD8+ T cell responses to IAV. This was true with respect to
primary IAV responses and was pronounced in female mice, suggesting that
MAIT cell functions may be partially governed by hormones in a previously
unappreciated way. I have also shown that i.p. co-administration of IAV with 5OP-RU induces MAIT cell accumulation in the peritoneal cavity. These MAIT cells
were readily activated, suggesting that they may accumulate at the site of IAV
inoculation to actively contribute to the ensuing immune response against the
viral invader. MAIT cells are abundant in the human body and should play an
important role in various aspects of host defense. It will be interesting to see what
functions and applications of MAIT cells are elucidated in the future.
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